-
1
-
-
84948403433
-
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus
-
Abdul-Ghani, M.A., Norton, L., DeFronzo, R.A., Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol 309 (2015), F889–F900.
-
(2015)
Am J Physiol Renal Physiol
, vol.309
, pp. F889-F900
-
-
Abdul-Ghani, M.A.1
Norton, L.2
DeFronzo, R.A.3
-
2
-
-
77953759683
-
Functional characterization of mouse/glucose transporter type 3b
-
Aljure, O., Dίez-Sampedro, A., Functional characterization of mouse/glucose transporter type 3b. Am J Physiol Cell Physiol 299 (2010), C58–C65.
-
(2010)
Am J Physiol Cell Physiol
, vol.299
, pp. C58-C65
-
-
Aljure, O.1
Dίez-Sampedro, A.2
-
3
-
-
55949115655
-
+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody
-
+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Physiol Cell Physiol 295 (2008), C475–C489.
-
(2008)
Am J Physiol Cell Physiol
, vol.295
, pp. C475-C489
-
-
Balen, D.1
Ljubojevic, M.2
Breljak, D.3
Brzica, H.4
Zlender, V.5
Koepsell, H.6
Sabolic, I.7
-
4
-
-
80054122252
-
NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1
-
Balteau, M., Tajeddine, N., de Meesters, C., Ginion, A., Des Rosiers, C., Brady, N.R., Sommereyns, C., et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res 92 (2011), 237–246.
-
(2011)
Cardiovasc Res
, vol.92
, pp. 237-246
-
-
Balteau, M.1
Tajeddine, N.2
de Meesters, C.3
Ginion, A.4
Des Rosiers, C.5
Brady, N.R.6
Sommereyns, C.7
-
5
-
-
70449729537
-
SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states
-
Banerjee, S.K., McGaffin, K.R., Pastor-Soler, N.M., Ahmad, F., SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 84 (2009), 111–118.
-
(2009)
Cardiovasc Res
, vol.84
, pp. 111-118
-
-
Banerjee, S.K.1
McGaffin, K.R.2
Pastor-Soler, N.M.3
Ahmad, F.4
-
6
-
-
84859773735
-
Mouse SGLT3a generates proton-activated currents but does not transport sugar
-
Barcelona, S., Menegaz, D., Dίez-Sampedro, A., Mouse SGLT3a generates proton-activated currents but does not transport sugar. Am J Cell Physiol 302 (2012), C1073–C1082.
-
(2012)
Am J Cell Physiol
, vol.302
, pp. C1073-C1082
-
-
Barcelona, S.1
Menegaz, D.2
Dίez-Sampedro, A.3
-
7
-
-
0036088671
-
Regulation of SGLT1 expression in response to Na(+) intake
-
Barfull, A., Garriga, C., Tauler, A., Planas, J.M., Regulation of SGLT1 expression in response to Na(+) intake. Am J Physiol Regul Integr Comp Physiol 282 (2002), R738–R743.
-
(2002)
Am J Physiol Regul Integr Comp Physiol
, vol.282
, pp. R738-R743
-
-
Barfull, A.1
Garriga, C.2
Tauler, A.3
Planas, J.M.4
-
8
-
-
0023162229
-
Fluid absorption by rat lung in situ: Pathways for sodium entry in the luminal membrane of alveolar epithelium
-
Basset, G., Crone, C., Saumon, G., Fluid absorption by rat lung in situ: Pathways for sodium entry in the luminal membrane of alveolar epithelium. J Physiol 384 (1987), 325–345.
-
(1987)
J Physiol
, vol.384
, pp. 325-345
-
-
Basset, G.1
Crone, C.2
Saumon, G.3
-
10
-
-
77956316182
-
A single amino acid change converts the sugar sensor SGLT3 into a sugar transporter
-
Bianchi, L., Dίez-Sampedro, A., A single amino acid change converts the sugar sensor SGLT3 into a sugar transporter. PLoS One, 5, 2010, e10241.
-
(2010)
PLoS One
, vol.5
-
-
Bianchi, L.1
Dίez-Sampedro, A.2
-
11
-
-
33645982255
-
From mice to men: insights into the insulin resistance syndromes
-
Biddinger, S.B., Kahn, C.R., From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 68 (2006), 123–158.
-
(2006)
Annu Rev Physiol
, vol.68
, pp. 123-158
-
-
Biddinger, S.B.1
Kahn, C.R.2
-
12
-
-
84928317576
-
Combination therapy for patients with uncontrolled type 2 diabetes mellitus: Adding empagliflozin to pioglitazone or pioglitazone plus metformin
-
Blevins, T., Combination therapy for patients with uncontrolled type 2 diabetes mellitus: Adding empagliflozin to pioglitazone or pioglitazone plus metformin. Expert Opin Drug Saf 14 (2015), 789–793.
-
(2015)
Expert Opin Drug Saf
, vol.14
, pp. 789-793
-
-
Blevins, T.1
-
13
-
-
84937763347
-
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
-
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thevenet, J., et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21 (2015), 512–517.
-
(2015)
Nat Med
, vol.21
, pp. 512-517
-
-
Bonner, C.1
Kerr-Conte, J.2
Gmyr, V.3
Queniat, G.4
Moerman, E.5
Thevenet, J.6
-
14
-
-
0020587246
-
Hemodynamically mediated glomerular injury and the progressive nature of kidney disease
-
Brenner, B.M., Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23 (1983), 647–655.
-
(1983)
Kidney Int
, vol.23
, pp. 647-655
-
-
Brenner, B.M.1
-
15
-
-
84962406727
-
Glucagon secretion from pancreatic α-cells
-
Briant, L., Salehi, A., Vergari, E., Zhang, Q., Rorsman, P., Glucagon secretion from pancreatic α-cells. Ups J Med Sci 121 (2016), 113–119.
-
(2016)
Ups J Med Sci
, vol.121
, pp. 113-119
-
-
Briant, L.1
Salehi, A.2
Vergari, E.3
Zhang, Q.4
Rorsman, P.5
-
16
-
-
20044376702
-
The pathobiology of diabetic complications: A unifying mechanism
-
Brownlee, M., The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54 (2005), 1615–1625.
-
(2005)
Diabetes
, vol.54
, pp. 1615-1625
-
-
Brownlee, M.1
-
17
-
-
33646927922
-
Glucose-sensing neurons of the hypothalamus
-
Burdakov, D., Luckman, S.M., Verkhratsky, A., Glucose-sensing neurons of the hypothalamus. Philos Trans R Soc B 360 (2005), 2227–2235.
-
(2005)
Philos Trans R Soc B
, vol.360
, pp. 2227-2235
-
-
Burdakov, D.1
Luckman, S.M.2
Verkhratsky, A.3
-
18
-
-
79251517382
-
Regulation of cancer cell metabolism
-
Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat Rev Cancer 11 (2011), 85–95.
-
(2011)
Nat Rev Cancer
, vol.11
, pp. 85-95
-
-
Cairns, R.A.1
Harris, I.S.2
Mak, T.W.3
-
19
-
-
84896713507
-
Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis
-
Cardani, D., Sardi, C., La Ferla, B., D'Orazio, G., Sommariva, M., Marcucci, F., et al. Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. Mol Cancer, 13, 2014, 23.
-
(2014)
Mol Cancer
, vol.13
, pp. 23
-
-
Cardani, D.1
Sardi, C.2
La Ferla, B.3
D'Orazio, G.4
Sommariva, M.5
Marcucci, F.6
-
20
-
-
53949106060
-
Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival
-
Casneuf, V.F., Fonteyne, P., Van Damme, N., Demetter, P., Pauwels, P., de Hemptinne, B., et al. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Investig 26 (2008), 852–859.
-
(2008)
Cancer Investig
, vol.26
, pp. 852-859
-
-
Casneuf, V.F.1
Fonteyne, P.2
Van Damme, N.3
Demetter, P.4
Pauwels, P.5
de Hemptinne, B.6
-
21
-
-
34248191309
-
Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes
-
Castaneda, F., Burse, A., Boland, W., Kinne, R.K., Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes. Int J Med Sci 4 (2007), 131–139.
-
(2007)
Int J Med Sci
, vol.4
, pp. 131-139
-
-
Castaneda, F.1
Burse, A.2
Boland, W.3
Kinne, R.K.4
-
22
-
-
77951701615
-
Protein kinase C mediated intracellular signaling pathways are involved in the regulation of sodium-dependent glucose co-transporter SGLT1 activity
-
Castaneda-Sceppa, C., Subramanian, S., Castaneda, F., Protein kinase C mediated intracellular signaling pathways are involved in the regulation of sodium-dependent glucose co-transporter SGLT1 activity. J Cell Biochem 109 (2010), 1109–1117.
-
(2010)
J Cell Biochem
, vol.109
, pp. 1109-1117
-
-
Castaneda-Sceppa, C.1
Subramanian, S.2
Castaneda, F.3
-
23
-
-
84884167643
-
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
-
Cefalu, W.T., Leiter, L.A., Yoon, K.H., Arias, P., Niskanen, L., Xie, J., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382 (2013), 941–950.
-
(2013)
Lancet
, vol.382
, pp. 941-950
-
-
Cefalu, W.T.1
Leiter, L.A.2
Yoon, K.H.3
Arias, P.4
Niskanen, L.5
Xie, J.6
-
24
-
-
0031405798
-
Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo
-
Cheeseman, C.I., Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Phys 273 (1997), R1965–R1971.
-
(1997)
Am J Phys
, vol.273
, pp. R1965-R1971
-
-
Cheeseman, C.I.1
-
25
-
-
79952721660
-
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
-
Chen, J., Williams, S., Ho, S., Loraine, H., Hagan, D., Whaley, J.M., Feder, J.N., Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1 (2010), 57–92.
-
(2010)
Diabetes Ther
, vol.1
, pp. 57-92
-
-
Chen, J.1
Williams, S.2
Ho, S.3
Loraine, H.4
Hagan, D.5
Whaley, J.M.6
Feder, J.N.7
-
26
-
-
84960439287
-
Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: Protocol for a systematic review and network meta-analysis
-
Chen, M., Xie, C.G., Gao, H., Zheng, H., Chen, Q., Fang, J.Q., Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: Protocol for a systematic review and network meta-analysis. BMJ Open, 6, 2016, e010252.
-
(2016)
BMJ Open
, vol.6
-
-
Chen, M.1
Xie, C.G.2
Gao, H.3
Zheng, H.4
Chen, Q.5
Fang, J.Q.6
-
27
-
-
84971663895
-
The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in type 1 diabetes
-
Cheng, S.T., Chen, L., Li, S.Y., Mayoux, E., Leung, P.S., The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in type 1 diabetes. PLoS One, 11, 2016, e0147391.
-
(2016)
PLoS One
, vol.11
-
-
Cheng, S.T.1
Chen, L.2
Li, S.Y.3
Mayoux, E.4
Leung, P.S.5
-
28
-
-
84892959743
-
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
-
Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O.E., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 28
-
-
Cherney, D.Z.1
Perkins, B.A.2
Soleymanlou, N.3
Har, R.4
Fagan, N.5
Johansen, O.E.6
-
29
-
-
84893214045
-
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
-
Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
-
(2014)
Circulation
, vol.129
, pp. 587-597
-
-
Cherney, D.Z.1
Perkins, B.A.2
Soleymanlou, N.3
Maione, M.4
Lai, V.5
Lee, A.6
-
30
-
-
84975153660
-
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria in patients with type 2 diabetes
-
Cherney, D., Lund, S.S., Perkins, B.A., Groop, P.-H., Cooper, M.E., Kaspers, S., et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria in patients with type 2 diabetes. Diabetologia, 2016, 10.1007/s00125-016-4008-2.
-
(2016)
Diabetologia
-
-
Cherney, D.1
Lund, S.S.2
Perkins, B.A.3
Groop, P.-H.4
Cooper, M.E.5
Kaspers, S.6
-
31
-
-
85052043849
-
Protein RS1 (RSC1A1) downregulates the exocytotic pathway of glucose transporter SGLT1 at low intracellular glucose via inhibition of ornithine decarboxylase
-
Chintalapathi, C., Keller, T., Müller, T.D., Gorboulev, V., Schäfer, N., Zilkowski, I., et al. Protein RS1 (RSC1A1) downregulates the exocytotic pathway of glucose transporter SGLT1 at low intracellular glucose via inhibition of ornithine decarboxylase. Mol Pharmacol 90 (2016), 1–15.
-
(2016)
Mol Pharmacol
, vol.90
, pp. 1-15
-
-
Chintalapathi, C.1
Keller, T.2
Müller, T.D.3
Gorboulev, V.4
Schäfer, N.5
Zilkowski, I.6
-
32
-
-
84894148643
-
Glucagon-like peptide-1: Glucose homeostasis and beyond
-
Cho, Y.M., Fujita, Y., Kieffer, T.J., Glucagon-like peptide-1: Glucose homeostasis and beyond. Annu Rev Physiol 76 (2014), 535–559.
-
(2014)
Annu Rev Physiol
, vol.76
, pp. 535-559
-
-
Cho, Y.M.1
Fujita, Y.2
Kieffer, T.J.3
-
33
-
-
0036446251
-
The effect of epidermal growth factor on the distribution of SGLT-1 in rabbit jejunum
-
Chung, B.M., Wallace, L.E., Hardin, J.A., Gall, D.G., The effect of epidermal growth factor on the distribution of SGLT-1 in rabbit jejunum. Can J Physiol Pharmacol 80 (2002), 872–878.
-
(2002)
Can J Physiol Pharmacol
, vol.80
, pp. 872-878
-
-
Chung, B.M.1
Wallace, L.E.2
Hardin, J.A.3
Gall, D.G.4
-
35
-
-
0028133185
-
Effect of arterial-portal glucose gradients and phloridzin on bile glucose levels in perfused rat liver
-
Crafer, S.M., Pryor, J.S., Dawson, A.P., Effect of arterial-portal glucose gradients and phloridzin on bile glucose levels in perfused rat liver. J Physiol 479 (1994), 281–289.
-
(1994)
J Physiol
, vol.479
, pp. 281-289
-
-
Crafer, S.M.1
Pryor, J.S.2
Dawson, A.P.3
-
36
-
-
66149088144
-
Nonalcoholic fatty liver disease in type 2 diabetes mellitus
-
Cusi, K., Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 16 (2009), 141–149.
-
(2009)
Curr Opin Endocrinol Diabetes Obes
, vol.16
, pp. 141-149
-
-
Cusi, K.1
-
37
-
-
4143151942
-
Pathogenesis of type 2 diabetes mellitus
-
DeFronzo, R.A., Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 88 (2004), 787–835.
-
(2004)
Med Clin North Am
, vol.88
, pp. 787-835
-
-
DeFronzo, R.A.1
-
38
-
-
64649104158
-
Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
-
DeFronzo, R.A., Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (2009), 773–795.
-
(2009)
Diabetes
, vol.58
, pp. 773-795
-
-
DeFronzo, R.A.1
-
39
-
-
84962725862
-
Revitalization of pioglitazone: the optimal agent to be combined with an SGLT2 inhibitor
-
DeFronzo, R.A., Chilton, R., Norton, L., Clarke, G., Ryder, R.E., Abdul-Ghani, M., Revitalization of pioglitazone: the optimal agent to be combined with an SGLT2 inhibitor. Diabetes Obes Metab 18 (2016), 454–462.
-
(2016)
Diabetes Obes Metab
, vol.18
, pp. 454-462
-
-
DeFronzo, R.A.1
Chilton, R.2
Norton, L.3
Clarke, G.4
Ryder, R.E.5
Abdul-Ghani, M.6
-
40
-
-
83655193529
-
The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia
-
DeFronzo, R.A., Davidson, J.A., Del, P.S., The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes Obes Metab 14 (2012), 5–14.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 5-14
-
-
DeFronzo, R.A.1
Davidson, J.A.2
Del, P.S.3
-
41
-
-
84891865819
-
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
-
DeFronzo, R.A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36 (2013), 3169–3176.
-
(2013)
Diabetes Care
, vol.36
, pp. 3169-3176
-
-
DeFronzo, R.A.1
Hompesch, M.2
Kasichayanula, S.3
Liu, X.4
Hong, Y.5
Pfister, M.6
-
42
-
-
84928176749
-
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin
-
DeFronzo, R.A., Lewin, A., Patel, S., Liu, D., Kaste, R., Woerle, H.J., Broedl, U.C., Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38 (2015), 384–393.
-
(2015)
Diabetes Care
, vol.38
, pp. 384-393
-
-
DeFronzo, R.A.1
Lewin, A.2
Patel, S.3
Liu, D.4
Kaste, R.5
Woerle, H.J.6
Broedl, U.C.7
-
43
-
-
84928426587
-
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-Year data
-
Del, P.S., Nauck, M., Duran-Garcia, S., Maffei, L., Rohwedder, K., Theuerkauf, A., Parikh, S., Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-Year data. Diabetes Obes Metab 17 (2015), 581–590.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 581-590
-
-
Del, P.S.1
Nauck, M.2
Duran-Garcia, S.3
Maffei, L.4
Rohwedder, K.5
Theuerkauf, A.6
Parikh, S.7
-
44
-
-
84876107265
-
The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing
-
Delaere, F., Duchampt, A., Mounien, L., Seyer, P., Duraffourd, C., Zitoun, C., et al. The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing. Mol Metab 2 (2012), 47–53.
-
(2012)
Mol Metab
, vol.2
, pp. 47-53
-
-
Delaere, F.1
Duchampt, A.2
Mounien, L.3
Seyer, P.4
Duraffourd, C.5
Zitoun, C.6
-
45
-
-
4644360065
-
Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB
-
Dieter, M., Palmada, M., Rajamanickam, J., Aydin, A., Busjahn, A., Boehmer, C.,.. Lang, F., Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB. Obes Res 12 (2004), 862–870.
-
(2004)
Obes Res
, vol.12
, pp. 862-870
-
-
Dieter, M.1
Palmada, M.2
Rajamanickam, J.3
Aydin, A.4
Busjahn, A.5
Boehmer, C.6
Lang, F.7
-
46
-
-
84930902626
-
Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release
-
Dobbins, R.L., Greenway, F.L., Chen, L., Liu, Y., Breed, S.L., Andrews, S.M., Wald, J.A., et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol 308 (2015), G946–G954.
-
(2015)
Am J Physiol Gastrointest Liver Physiol
, vol.308
, pp. G946-G954
-
-
Dobbins, R.L.1
Greenway, F.L.2
Chen, L.3
Liu, Y.4
Breed, S.L.5
Andrews, S.M.6
Wald, J.A.7
-
47
-
-
84951932095
-
Regulation of intestinal SGLT1 by catestin in hyperleptinemic type 2 diabetic mice
-
Dominguez Rieg, J.A., Chirasani, V.R., Koepsell, H., Senapati, S., Mahata, S.K., Rieg, T., Regulation of intestinal SGLT1 by catestin in hyperleptinemic type 2 diabetic mice. Lab Investig 96 (2016), 98–111.
-
(2016)
Lab Investig
, vol.96
, pp. 98-111
-
-
Dominguez Rieg, J.A.1
Chirasani, V.R.2
Koepsell, H.3
Senapati, S.4
Mahata, S.K.5
Rieg, T.6
-
48
-
-
12744273119
-
Luminal leptin induces rapid inhibition of active intestinal absorption of glucose mediated by sodium-glucose cotransporter 1
-
Ducroc, R., Guilmeau, S., Akasbi, K., Devaud, H., Buyse, M., Bado, A., Luminal leptin induces rapid inhibition of active intestinal absorption of glucose mediated by sodium-glucose cotransporter 1. Diabetes 54 (2005), 348–354.
-
(2005)
Diabetes
, vol.54
, pp. 348-354
-
-
Ducroc, R.1
Guilmeau, S.2
Akasbi, K.3
Devaud, H.4
Buyse, M.5
Bado, A.6
-
49
-
-
0030773094
-
+/glucose co-transporter (SGLT1) in experimental diabetes
-
+/glucose co-transporter (SGLT1) in experimental diabetes. Biochem Soc Trans, 25, 1997, 479S.
-
(1997)
Biochem Soc Trans
, vol.25
, pp. 479S
-
-
Dyer, J.1
Garner, A.2
Wood, I.S.3
Sharma, A.K.4
Chandranath, I.5
Shirazi-Beechey, S.P.6
-
50
-
-
0036080516
-
Expression of monosaccharide transporters in intestine of diabetic humans
-
Dyer, J., Wood, I.S., Palejwala, A., Ellis, A., Shirazi-Beechey, S.P., Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol 282 (2002), G241–G248.
-
(2002)
Am J Physiol Gastrointest Liver Physiol
, vol.282
, pp. G241-G248
-
-
Dyer, J.1
Wood, I.S.2
Palejwala, A.3
Ellis, A.4
Shirazi-Beechey, S.P.5
-
51
-
-
0141705347
-
A glucose sensor hiding in a family of transporters
-
Dίez-Sampedro, A., Hirayama, B.A., Osswald, C., Gorboulev, V., Baumgarten, K., Volk, C.,.. Koepsell, H., A glucose sensor hiding in a family of transporters. Proc Natl Sci USA 100 (2003), 11753–11758.
-
(2003)
Proc Natl Sci USA
, vol.100
, pp. 11753-11758
-
-
Dίez-Sampedro, A.1
Hirayama, B.A.2
Osswald, C.3
Gorboulev, V.4
Baumgarten, K.5
Volk, C.6
Koepsell, H.7
-
52
-
-
1842737553
-
Localization of the Na(+)-D-glucose cotransporter SGLT1 in the blood–brain barrier
-
Elfeber, K., Köhler, A., Lutzenburg, M., Osswald, C., Galla, H.J., Witte, O.W., Koepsell, H., Localization of the Na(+)-D-glucose cotransporter SGLT1 in the blood–brain barrier. Histochem Cell Biol 121 (2004), 201–207.
-
(2004)
Histochem Cell Biol
, vol.121
, pp. 201-207
-
-
Elfeber, K.1
Köhler, A.2
Lutzenburg, M.3
Osswald, C.4
Galla, H.J.5
Witte, O.W.6
Koepsell, H.7
-
54
-
-
84964608804
-
Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients
-
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., et al. Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients. Diabetes 65 (2016), 1190–1195.
-
(2016)
Diabetes
, vol.65
, pp. 1190-1195
-
-
Ferrannini, E.1
Baldi, S.2
Frascerra, S.3
Astiarraga, B.4
Heise, T.5
Bizzotto, R.6
-
55
-
-
84893872877
-
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
-
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
-
(2014)
J Clin Invest
, vol.124
, pp. 499-508
-
-
Ferrannini, E.1
Muscelli, E.2
Frascerra, S.3
Baldi, S.4
Mari, A.5
Heise, T.6
-
56
-
-
0031034371
-
Regulation of intestinal sugar transport
-
Ferraris, R.P., Diamond, J., Regulation of intestinal sugar transport. Physiol Rev 77 (1997), 257–302.
-
(1997)
Physiol Rev
, vol.77
, pp. 257-302
-
-
Ferraris, R.P.1
Diamond, J.2
-
57
-
-
77955065720
-
High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: Results of a 6-year follow-up
-
Ficociello, L.H., Rosolowsky, E.T., Niewczas, M.A., Maselli, N.J., Weinberg, J.M., Aschengrau, A., et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: Results of a 6-year follow-up. Diabetes Care 33 (2010), 1337–1343.
-
(2010)
Diabetes Care
, vol.33
, pp. 1337-1343
-
-
Ficociello, L.H.1
Rosolowsky, E.T.2
Niewczas, M.A.3
Maselli, N.J.4
Weinberg, J.M.5
Aschengrau, A.6
-
58
-
-
70350674915
-
Novel shuttling domain in a regulator (RSC1A1) of transporter SGLT1 steers cell cycle-dependent nuclear location
-
Filatova, A., Leyerer, M., Gorboulev, V., Chintalapati, C., Reinders, Y., Müller, T.D., et al. Novel shuttling domain in a regulator (RSC1A1) of transporter SGLT1 steers cell cycle-dependent nuclear location. Traffic 10 (2009), 1599–1618.
-
(2009)
Traffic
, vol.10
, pp. 1599-1618
-
-
Filatova, A.1
Leyerer, M.2
Gorboulev, V.3
Chintalapati, C.4
Reinders, Y.5
Müller, T.D.6
-
59
-
-
33748328212
-
Luminal glucose sensing in the rat intestine has characteristics of a sodium-glucose transporter
-
Freeman, S.L., Bohan, D., Darcel, N., Raybould, H.E., Luminal glucose sensing in the rat intestine has characteristics of a sodium-glucose transporter. Am J Physiol Gastrointest Liver Physiol 291 (2006), G439–G445.
-
(2006)
Am J Physiol Gastrointest Liver Physiol
, vol.291
, pp. G439-G445
-
-
Freeman, S.L.1
Bohan, D.2
Darcel, N.3
Raybould, H.E.4
-
60
-
-
84899904943
-
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
-
Fujita, Y., Inagaki, N., Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig 5 (2014), 265–275.
-
(2014)
J Diabetes Investig
, vol.5
, pp. 265-275
-
-
Fujita, Y.1
Inagaki, N.2
-
61
-
-
0031742335
-
Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima fatty rats
-
Fujita, Y., Kojima, H., Hidaka, H., Fujimiya, M., Kashiwagi, A., Kikkawa, R., Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima fatty rats. Diabetologia 41 (1998), 1459–1466.
-
(1998)
Diabetologia
, vol.41
, pp. 1459-1466
-
-
Fujita, Y.1
Kojima, H.2
Hidaka, H.3
Fujimiya, M.4
Kashiwagi, A.5
Kikkawa, R.6
-
62
-
-
84867847742
-
Structure–activity relationship studies of 4-benzyl-1H-pyrazol-3-yl beta-D-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia
-
Fushimi, N., Fujikura, H., Shiohara, H., Teranishi, H., Shimizu, K., Yonekubo, S., et al. Structure–activity relationship studies of 4-benzyl-1H-pyrazol-3-yl beta-D-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia. Bioorg Med Chem 20 (2012), 6598–6612.
-
(2012)
Bioorg Med Chem
, vol.20
, pp. 6598-6612
-
-
Fushimi, N.1
Fujikura, H.2
Shiohara, H.3
Teranishi, H.4
Shimizu, K.5
Yonekubo, S.6
-
63
-
-
84907659467
-
Positron emission tomography (PET) in oncology
-
Gallamini, A., Zwarthoed, C., Borra, A., Positron emission tomography (PET) in oncology. Cancers (Basel) 6 (2014), 1821–1889.
-
(2014)
Cancers (Basel)
, vol.6
, pp. 1821-1889
-
-
Gallamini, A.1
Zwarthoed, C.2
Borra, A.3
-
64
-
-
84977633501
-
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
-
Gallo, L.A., Ward, M.S., Fotheringham, A.K., Zhuang, A., Borg, D.J., Flemming, N.B., et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep, 6, 2016, 26428.
-
(2016)
Sci Rep
, vol.6
, pp. 26428
-
-
Gallo, L.A.1
Ward, M.S.2
Fotheringham, A.K.3
Zhuang, A.4
Borg, D.J.5
Flemming, N.B.6
-
65
-
-
84923527667
-
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
-
Gallo, L.A., Wright, E.M., Vallon, V., Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. Diab Vasc Dis Res 12 (2015), 78–89.
-
(2015)
Diab Vasc Dis Res
, vol.12
, pp. 78-89
-
-
Gallo, L.A.1
Wright, E.M.2
Vallon, V.3
-
66
-
-
57749111596
-
Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond
-
Ganapathy, V., Thangaraju, M., Prasad, P.D., Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond. Pharmacol Ther 121 (2009), 29–40.
-
(2009)
Pharmacol Ther
, vol.121
, pp. 29-40
-
-
Ganapathy, V.1
Thangaraju, M.2
Prasad, P.D.3
-
67
-
-
84888798201
-
Tumor glycolysis as a target for cancer therapy: Progress and prospects
-
Ganapathy-Kanniappan, S., Geschwind, J.F., Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer, 12, 2013, 152.
-
(2013)
Mol Cancer
, vol.12
, pp. 152
-
-
Ganapathy-Kanniappan, S.1
Geschwind, J.F.2
-
68
-
-
84905238756
-
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
-
Gembardt, F., Bartaun, C., Jarzebska, N., Mayoux, E., Todorov, V.T., Hohenstein, B., Hugo, C., The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307 (2014), F317–F325.
-
(2014)
Am J Physiol Renal Physiol
, vol.307
, pp. F317-F325
-
-
Gembardt, F.1
Bartaun, C.2
Jarzebska, N.3
Mayoux, E.4
Todorov, V.T.5
Hohenstein, B.6
Hugo, C.7
-
70
-
-
77955517441
-
Diabetes and cancer: A consensus report
-
Giovannucci, E., Harlan, D.H., Archer, M.C., Bergenstal, R.M., Gapstur, S.M., et al. Diabetes and cancer: A consensus report. Diabetes Care 33 (2010), 1674–1685.
-
(2010)
Diabetes Care
, vol.33
, pp. 1674-1685
-
-
Giovannucci, E.1
Harlan, D.H.2
Archer, M.C.3
Bergenstal, R.M.4
Gapstur, S.M.5
-
71
-
-
0023179755
-
Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats
-
Goodlad, R.A., Wilson, T.J., Lenton, W., Gregory, H., McCullagh, K.G., Wright, N.A., Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats. Gut 28 (1987), 573–582.
-
(1987)
Gut
, vol.28
, pp. 573-582
-
-
Goodlad, R.A.1
Wilson, T.J.2
Lenton, W.3
Gregory, H.4
McCullagh, K.G.5
Wright, N.A.6
-
73
-
-
0242391821
-
Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: a study in GLUT2-null mice
-
Gouyon, F., Caillaud, L., Carrière, V., Klein, C., Dalet, V., Citadelle, D., et al. Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: a study in GLUT2-null mice. J Physiol 552 (2003), 823–832.
-
(2003)
J Physiol
, vol.552
, pp. 823-832
-
-
Gouyon, F.1
Caillaud, L.2
Carrière, V.3
Klein, C.4
Dalet, V.5
Citadelle, D.6
-
74
-
-
83655184724
-
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
-
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D.E., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 83-90
-
-
Grempler, R.1
Thomas, L.2
Eckhardt, M.3
Himmelsbach, F.4
Sauer, A.5
Sharp, D.E.6
-
75
-
-
33846856711
-
Alpha-cells of the endocrine pancreas: 35 Years of research but the enigma remains
-
Gromada, J., Franklin, I., Wollheim, C.B., Alpha-cells of the endocrine pancreas: 35 Years of research but the enigma remains. Endocr Rev 28 (2007), 84–116.
-
(2007)
Endocr Rev
, vol.28
, pp. 84-116
-
-
Gromada, J.1
Franklin, I.2
Wollheim, C.B.3
-
76
-
-
84655170171
-
Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis
-
Guo, G.F., Cai, Y.C., Zhang, B., Xu, R.H., Qiu, H.J., Xia, L.P., et al. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol 28 (2011), S197–S203.
-
(2011)
Med Oncol
, vol.28
, pp. S197-S203
-
-
Guo, G.F.1
Cai, Y.C.2
Zhang, B.3
Xu, R.H.4
Qiu, H.J.5
Xia, L.P.6
-
77
-
-
0016032989
-
Glucose reabsorption from bile. Evidence for a biliohepatic circulation
-
Guzelian, P., Boyer, J.L., Glucose reabsorption from bile. Evidence for a biliohepatic circulation. J Clin Invest 53 (1974), 526–535.
-
(1974)
J Clin Invest
, vol.53
, pp. 526-535
-
-
Guzelian, P.1
Boyer, J.L.2
-
78
-
-
48249146624
-
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
-
Han, S., Hagan, D.L., Taylor, J.R., Xin, L., Meng, W., Biller, S.A., et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57 (2008), 1723–1729.
-
(2008)
Diabetes
, vol.57
, pp. 1723-1729
-
-
Han, S.1
Hagan, D.L.2
Taylor, J.R.3
Xin, L.4
Meng, W.5
Biller, S.A.6
-
80
-
-
80555154280
-
High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR
-
Han, L., Ma, Q., Li, J., Liu, H., Li, W., Ma, G., et al. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One, 6, 2011, e27074.
-
(2011)
PLoS One
, vol.6
-
-
Han, L.1
Ma, Q.2
Li, J.3
Liu, H.4
Li, W.5
Ma, G.6
-
81
-
-
84864276800
-
Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma
-
Hanabata, Y., Nakajima, Y., Morita, K., Kayamori, K., Omura, K., Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. Odontology 100 (2011), 156–163.
-
(2011)
Odontology
, vol.100
, pp. 156-163
-
-
Hanabata, Y.1
Nakajima, Y.2
Morita, K.3
Kayamori, K.4
Omura, K.5
-
82
-
-
84917742055
-
Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy
-
Hansen, L., Iqbal, N., Ekholm, E., Cook, W., Hirshberg, B., Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract 20 (2014), 1187–1197.
-
(2014)
Endocr Pract
, vol.20
, pp. 1187-1197
-
-
Hansen, L.1
Iqbal, N.2
Ekholm, E.3
Cook, W.4
Hirshberg, B.5
-
83
-
-
67649392260
-
The development of glucose intolerance after focal cerebral ischemia participates in subsequent neuronal damage
-
Harada, S., Fujita, W.H., Shichi, K., Tokuyama, S., The development of glucose intolerance after focal cerebral ischemia participates in subsequent neuronal damage. Brain Res 1279 (2009), 174–181.
-
(2009)
Brain Res
, vol.1279
, pp. 174-181
-
-
Harada, S.1
Fujita, W.H.2
Shichi, K.3
Tokuyama, S.4
-
84
-
-
0029737627
-
Effect of luminal epidermal growth factor on enterocyte glucose and proline transport
-
Hardin, J.A., Wong, J.K., Cheeseman, C.I., Gall, D.G., Effect of luminal epidermal growth factor on enterocyte glucose and proline transport. Am J Physiol Gastrointest Liver Physiol 271 (1996), G509–G515.
-
(1996)
Am J Physiol Gastrointest Liver Physiol
, vol.271
, pp. G509-G515
-
-
Hardin, J.A.1
Wong, J.K.2
Cheeseman, C.I.3
Gall, D.G.4
-
85
-
-
84901455931
-
Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
-
Haring, H.U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U.C., Woerle, H.J., Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37 (2014), 1650–1659.
-
(2014)
Diabetes Care
, vol.37
, pp. 1650-1659
-
-
Haring, H.U.1
Merker, L.2
Seewaldt-Becker, E.3
Weimer, M.4
Meinicke, T.5
Broedl, U.C.6
Woerle, H.J.7
-
86
-
-
84875123211
-
The ABCs of membrane transporters in health and disease (SLC series): Introduction
-
Hediger, M.A., Clémençon, B., Burrier, R.E., Bruford, E.A., The ABCs of membrane transporters in health and disease (SLC series): Introduction. Mol Asp Med 34 (2013), 95–107.
-
(2013)
Mol Asp Med
, vol.34
, pp. 95-107
-
-
Hediger, M.A.1
Clémençon, B.2
Burrier, R.E.3
Bruford, E.A.4
-
88
-
-
0028863503
-
Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype
-
Heilig, C.W., Concepcion, L.A., Riser, B.L., Freytag, S.O., Zhu, M., Cortes, P., Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96 (1995), 1802–1814.
-
(1995)
J Clin Invest
, vol.96
, pp. 1802-1814
-
-
Heilig, C.W.1
Concepcion, L.A.2
Riser, B.L.3
Freytag, S.O.4
Zhu, M.5
Cortes, P.6
-
89
-
-
84860218907
-
Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
-
Henry, R.R., Murray, A.V., Marmolejo, M.H., Hennicken, D., Ptaszynska, A., List, J.F., Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66 (2012), 446–456.
-
(2012)
Int J Clin Pract
, vol.66
, pp. 446-456
-
-
Henry, R.R.1
Murray, A.V.2
Marmolejo, M.H.3
Hennicken, D.4
Ptaszynska, A.5
List, J.F.6
-
90
-
-
84930580133
-
Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
-
Hinnen, D., Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 6 (2015), 92–102.
-
(2015)
Ther Adv Endocrinol Metab
, vol.6
, pp. 92-102
-
-
Hinnen, D.1
-
91
-
-
0032486248
-
Cholecystokinin decreases intestinal hexose absorption by a parallel reduction in SGLT1 abundance in the brush-border membrane
-
Hirsh, A.J., Cheeseman, C.I., Cholecystokinin decreases intestinal hexose absorption by a parallel reduction in SGLT1 abundance in the brush-border membrane. J Biol Chem 273 (1998), 14545–14549.
-
(1998)
J Biol Chem
, vol.273
, pp. 14545-14549
-
-
Hirsh, A.J.1
Cheeseman, C.I.2
-
92
-
-
35748957503
-
The physiology of glucagon-like peptide 1
-
Holst, J.J., The physiology of glucagon-like peptide 1. Physiol Rev 87 (2007), 1409–1439.
-
(2007)
Physiol Rev
, vol.87
, pp. 1409-1439
-
-
Holst, J.J.1
-
93
-
-
79955661128
-
Stimulation of the glucose carrier SGLT1 by JAK2
-
Hosseinzadeh, Z., Bhavsar, S.K., Shojaiefard, M., Saxena, A., Merches, K., Sopjani, M., et al. Stimulation of the glucose carrier SGLT1 by JAK2. Biochem Biophys Res Commun 408 (2011), 208–213.
-
(2011)
Biochem Biophys Res Commun
, vol.408
, pp. 208-213
-
-
Hosseinzadeh, Z.1
Bhavsar, S.K.2
Shojaiefard, M.3
Saxena, A.4
Merches, K.5
Sopjani, M.6
-
94
-
-
27944443159
-
Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cells
-
Ikari, A., Nagatani, Y., Tsukimoto, M., Harada, H., Miwa, M., Takagi, K., Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cells. Biochim Biophys Acta 1717 (2005), 109–117.
-
(2005)
Biochim Biophys Acta
, vol.1717
, pp. 109-117
-
-
Ikari, A.1
Nagatani, Y.2
Tsukimoto, M.3
Harada, H.4
Miwa, M.5
Takagi, K.6
-
95
-
-
0037031858
-
Up-regulation of sodium-dependent glucose transporter by interaction with heat shock protein 70
-
Ikari, A., Nakano, M., Kawano, K., Suketa, Y., Up-regulation of sodium-dependent glucose transporter by interaction with heat shock protein 70. J Biol Chem 277 (2002), 33338–33343.
-
(2002)
J Biol Chem
, vol.277
, pp. 33338-33343
-
-
Ikari, A.1
Nakano, M.2
Kawano, K.3
Suketa, Y.4
-
96
-
-
0034820481
-
SGLT gene expression in primary lung cancers and their metastatic lesions
-
Ishikawa, N., Oguri, T., Isobe, T., Fujitaka, K., Kohno, N., SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res 92 (2001), 874–879.
-
(2001)
Jpn J Cancer Res
, vol.92
, pp. 874-879
-
-
Ishikawa, N.1
Oguri, T.2
Isobe, T.3
Fujitaka, K.4
Kohno, N.5
-
97
-
-
84896701131
-
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study
-
Jabbour, S.A., Hardy, E., Sugg, J., Parikh, S., Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37 (2014), 740–750.
-
(2014)
Diabetes Care
, vol.37
, pp. 740-750
-
-
Jabbour, S.A.1
Hardy, E.2
Sugg, J.3
Parikh, S.4
-
98
-
-
84957581904
-
Impact of reduced renal function on the glucose-lowering effects of luseogliflozin, a selective SGLT2 inhibitor, assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus
-
Jinnouchi, H., Nozaki, K., Watase, H., Omiya, H., Sakai, S., Samukawa, Y., Impact of reduced renal function on the glucose-lowering effects of luseogliflozin, a selective SGLT2 inhibitor, assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus. Adv Ther 33 (2016), 460–479.
-
(2016)
Adv Ther
, vol.33
, pp. 460-479
-
-
Jinnouchi, H.1
Nozaki, K.2
Watase, H.3
Omiya, H.4
Sakai, S.5
Samukawa, Y.6
-
99
-
-
34249929950
-
Development of diabetes in obese, insulin-resistant mice: essential role of dietary carbohydrate in beta cell destruction
-
Jurgens, H.S., Neschen, S., Ortmann, S., Scherneck, S., Schmolz, K., Schuler, G., et al. Development of diabetes in obese, insulin-resistant mice: essential role of dietary carbohydrate in beta cell destruction. Diabetologia 50 (2007), 1481–1489.
-
(2007)
Diabetologia
, vol.50
, pp. 1481-1489
-
-
Jurgens, H.S.1
Neschen, S.2
Ortmann, S.3
Scherneck, S.4
Schmolz, K.5
Schuler, G.6
-
100
-
-
0030851867
-
Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats
-
Kamran, M., Peterson, R.G., Dominguez, J.H., Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 8 (1997), 943–948.
-
(1997)
J Am Soc Nephrol
, vol.8
, pp. 943-948
-
-
Kamran, M.1
Peterson, R.G.2
Dominguez, J.H.3
-
101
-
-
0028044629
-
+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism of D-glucose
-
+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism of D-glucose. J Clin Invest 93 (1994), 397–404.
-
(1994)
J Clin Invest
, vol.93
, pp. 397-404
-
-
Kanai, Y.1
Lee, W.-S.2
You, G.3
Brown, D.4
Hediger, M.A.5
-
102
-
-
1442276966
-
Physiological and molecular characteristics of rat hypothalamic ventromedial nucleus glucosensing neurons
-
Kang, L., Routh, V.H., Kuzhikandathil, E.V., Gaspers, L.D., Levin, B.E., Physiological and molecular characteristics of rat hypothalamic ventromedial nucleus glucosensing neurons. Diabetes 53 (2004), 549–559.
-
(2004)
Diabetes
, vol.53
, pp. 549-559
-
-
Kang, L.1
Routh, V.H.2
Kuzhikandathil, E.V.3
Gaspers, L.D.4
Levin, B.E.5
-
103
-
-
84955619589
-
Nuclear mechanisms of insulin resistance
-
Kang, S., Tsai, L.T., Rosen, E.D., Nuclear mechanisms of insulin resistance. Trends Cell Biol 26 (2016), 341–351.
-
(2016)
Trends Cell Biol
, vol.26
, pp. 341-351
-
-
Kang, S.1
Tsai, L.T.2
Rosen, E.D.3
-
104
-
-
84938710060
-
Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia–reperfusion injury in mice
-
Kashiwagi, Y., Nagoshi, T., Yoshino, T., Tanaka, T.D., Ito, K., Harada, T., et al. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia–reperfusion injury in mice. PLoS One, 10, 2015, e0130605.
-
(2015)
PLoS One
, vol.10
-
-
Kashiwagi, Y.1
Nagoshi, T.2
Yoshino, T.3
Tanaka, T.D.4
Ito, K.5
Harada, T.6
-
105
-
-
48249101312
-
Role of Sp1 and HNF1 transcription factors in SGLT1 regulation during chronic intestinal inflammation
-
Kekuda, R., Saha, P., Sundaram, U., Role of Sp1 and HNF1 transcription factors in SGLT1 regulation during chronic intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 294 (2008), G1354–G1361.
-
(2008)
Am J Physiol Gastrointest Liver Physiol
, vol.294
, pp. G1354-G1361
-
-
Kekuda, R.1
Saha, P.2
Sundaram, U.3
-
106
-
-
84959511891
-
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
-
Kern, M., Kloting, N., Mark, M., Mayoux, E., Klein, T., Bluher, M., The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism 65 (2016), 114–123.
-
(2016)
Metabolism
, vol.65
, pp. 114-123
-
-
Kern, M.1
Kloting, N.2
Mark, M.3
Mayoux, E.4
Klein, T.5
Bluher, M.6
-
107
-
-
84897394040
-
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
-
Kohan, D.E., Fioretto, P., Tang, W., List, J.F., Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85 (2014), 962–971.
-
(2014)
Kidney Int
, vol.85
, pp. 962-971
-
-
Kohan, D.E.1
Fioretto, P.2
Tang, W.3
List, J.F.4
-
108
-
-
84878060305
-
Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats
-
Kojima, N., Williams, J.M., Takahashi, T., Miyata, N., Roman, R.J., Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 345 (2013), 464–472.
-
(2013)
J Pharmacol Exp Ther
, vol.345
, pp. 464-472
-
-
Kojima, N.1
Williams, J.M.2
Takahashi, T.3
Miyata, N.4
Roman, R.J.5
-
109
-
-
84961615237
-
Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction
-
Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One, 11, 2016, e0151511.
-
(2016)
PLoS One
, vol.11
-
-
Komiya, C.1
Tsuchiya, K.2
Shiba, K.3
Miyachi, Y.4
Furuke, S.5
Shimazu, N.6
-
110
-
-
67349275999
-
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
-
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., Pfister, M., Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85 (2009), 513–519.
-
(2009)
Clin Pharmacol Ther
, vol.85
, pp. 513-519
-
-
Komoroski, B.1
Vachharajani, N.2
Feng, Y.3
Li, L.4
Kornhauser, D.5
Pfister, M.6
-
111
-
-
0035976973
-
The plasma membrane-associated protein RS1 decreases transcription of the transporter SGLT1 in confluent LLC-PK1 cells
-
Korn, T., Kühlkamp, T., Track, C., Schatz, I., Baumgarten, K., Gorboulev, V., Koepsell, H., The plasma membrane-associated protein RS1 decreases transcription of the transporter SGLT1 in confluent LLC-PK1 cells. J Biol Chem 276 (2001), 45330–45340.
-
(2001)
J Biol Chem
, vol.276
, pp. 45330-45340
-
-
Korn, T.1
Kühlkamp, T.2
Track, C.3
Schatz, I.4
Baumgarten, K.5
Gorboulev, V.6
Koepsell, H.7
-
112
-
-
84892477577
-
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
-
Kovacs, C.S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H.J., Broedl, U.C., Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16 (2014), 147–158.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 147-158
-
-
Kovacs, C.S.1
Seshiah, V.2
Swallow, R.3
Jones, R.4
Rattunde, H.5
Woerle, H.J.6
Broedl, U.C.7
-
113
-
-
84924924178
-
The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents
-
Kowalski, G.M., Bruce, C.R., The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. Am J Physiol Endocrinol Metab 307 (2014), E859–E871.
-
(2014)
Am J Physiol Endocrinol Metab
, vol.307
, pp. E859-E871
-
-
Kowalski, G.M.1
Bruce, C.R.2
-
114
-
-
84959342655
-
Patient considerations in type 2 diabetes — Role of combination dapagliflozin-metformin XR
-
Kuecker, C.M., Vivian, E.M., Patient considerations in type 2 diabetes — Role of combination dapagliflozin-metformin XR. Diabetes Metab Syndr Obes 9 (2016), 25–35.
-
(2016)
Diabetes Metab Syndr Obes
, vol.9
, pp. 25-35
-
-
Kuecker, C.M.1
Vivian, E.M.2
-
115
-
-
84877922239
-
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data
-
Kurosaki, E., Ogasawara, H., Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther 139 (2013), 51–59.
-
(2013)
Pharmacol Ther
, vol.139
, pp. 51-59
-
-
Kurosaki, E.1
Ogasawara, H.2
-
116
-
-
84975266782
-
Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of type 2 diabetes
-
Kushner, P., Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of type 2 diabetes. Women's Health (Lond Engl) 12 (2016), 379–388.
-
(2016)
Women's Health (Lond Engl)
, vol.12
, pp. 379-388
-
-
Kushner, P.1
-
117
-
-
84862759133
-
Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma
-
Lai, B., Xiao, Y., Pu, H., Cao, Q., Jing, H., Liu, X., Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma. Arch Gynecol Obstet 285 (2012), 1455–1461.
-
(2012)
Arch Gynecol Obstet
, vol.285
, pp. 1455-1461
-
-
Lai, B.1
Xiao, Y.2
Pu, H.3
Cao, Q.4
Jing, H.5
Liu, X.6
-
118
-
-
84880850027
-
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
-
Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 853-862
-
-
Lambers Heerspink, H.J.1
de Zeeuw, D.2
Wie, L.3
Leslie, B.4
List, J.5
-
119
-
-
33749500123
-
(Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms
-
Lang, F., Bohmer, C., Palmada, M., Seebohm, G., Strutz-Seebohm, N., Vallon, V., (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev 86 (2006), 1151–1178.
-
(2006)
Physiol Rev
, vol.86
, pp. 1151-1178
-
-
Lang, F.1
Bohmer, C.2
Palmada, M.3
Seebohm, G.4
Strutz-Seebohm, N.5
Vallon, V.6
-
120
-
-
84887997289
-
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial
-
Lavalle-Gonzalez, F.J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., Meininger, G., Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia 56 (2013), 2582–2592.
-
(2013)
Diabetologia
, vol.56
, pp. 2582-2592
-
-
Lavalle-Gonzalez, F.J.1
Januszewicz, A.2
Davidson, J.3
Tong, C.4
Qiu, R.5
Canovatchel, W.6
Meininger, G.7
-
121
-
-
0028234548
-
+/glucose cotransporter. Re-evaluation of function and distribution of expression
-
+/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 269 (1994), 12032–12039.
-
(1994)
J Biol Chem
, vol.269
, pp. 12032-12039
-
-
Lee, S.-W.1
Kanai, Y.2
Wells, R.G.3
Hediger, M.A.4
-
122
-
-
84924811717
-
Distinct action of α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion
-
Lee, E.Y., Kaneko, S., Jutabha, P., Zhang, X., Seino, S., Jomori, T., et al. Distinct action of α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion. J Endocrinol 224 (2015), 205–214.
-
(2015)
J Endocrinol
, vol.224
, pp. 205-214
-
-
Lee, E.Y.1
Kaneko, S.2
Jutabha, P.3
Zhang, X.4
Seino, S.5
Jomori, T.6
-
123
-
-
0000309353
-
+/glucose cotransporter (SGLT1) mRNA stability. Interaction of a nucleocytoplasmic protein with a regulatory domain in the 3′-untranslated region critical for stabilization
-
+/glucose cotransporter (SGLT1) mRNA stability. Interaction of a nucleocytoplasmic protein with a regulatory domain in the 3′-untranslated region critical for stabilization. J Biol Chem 275 (2000), 33998–34008.
-
(2000)
J Biol Chem
, vol.275
, pp. 33998-34008
-
-
Lee, W.Y.1
Loflin, P.2
Clancey, C.J.3
Peng, H.4
Lever, J.E.5
-
124
-
-
84940110139
-
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study
-
Leiter, L.A., Yoon, K.H., Arias, P., Langslet, G., Xie, J., Balis, D.A., et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 38 (2015), 355–364.
-
(2015)
Diabetes Care
, vol.38
, pp. 355-364
-
-
Leiter, L.A.1
Yoon, K.H.2
Arias, P.3
Langslet, G.4
Xie, J.5
Balis, D.A.6
-
125
-
-
85006733634
-
SGK1 inhibitor reverses hyperglycemia partially through decreasing glucose absorption
-
Li, P., Hao, Y., Pan, F.H., Zhang, M., Ma, J.Q., Zhu, D.L., SGK1 inhibitor reverses hyperglycemia partially through decreasing glucose absorption. J Mol Endocrinol 56 (2016), 301–309, 10.1530/JME-15-0285.
-
(2016)
J Mol Endocrinol
, vol.56
, pp. 301-309
-
-
Li, P.1
Hao, Y.2
Pan, F.H.3
Zhang, M.4
Ma, J.Q.5
Zhu, D.L.6
-
126
-
-
84912533839
-
Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and meta-analysis
-
Liakos, A., Karagiannis, T., Athanasiadou, E., Sarigianni, M., Mainou, M., Papatheodorou, K., et al. Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 16 (2014), 984–993.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 984-993
-
-
Liakos, A.1
Karagiannis, T.2
Athanasiadou, E.3
Sarigianni, M.4
Mainou, M.5
Papatheodorou, K.6
-
127
-
-
84930580913
-
Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus
-
Liakos, A., Karagiannis, T., Bekiari, E., Boura, P., Tsapas, A., Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 6 (2015), 61–67.
-
(2015)
Ther Adv Endocrinol Metab
, vol.6
, pp. 61-67
-
-
Liakos, A.1
Karagiannis, T.2
Bekiari, E.3
Boura, P.4
Tsapas, A.5
-
128
-
-
65349196064
-
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes
-
List, J.F., Woo, V., Morales, E., Tang, W., Fiedorek, F.T., Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32 (2009), 650–657.
-
(2009)
Diabetes Care
, vol.32
, pp. 650-657
-
-
List, J.F.1
Woo, V.2
Morales, E.3
Tang, W.4
Fiedorek, F.T.5
-
129
-
-
84902240389
-
Luseogliflozin: First global approval
-
Markham, A., Elkinson, S., Luseogliflozin: First global approval. Drugs 74 (2014), 945–950.
-
(2014)
Drugs
, vol.74
, pp. 945-950
-
-
Markham, A.1
Elkinson, S.2
-
130
-
-
0345327784
-
Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane
-
Marks, J., Carvou, N.J.C., Debnam, E.S., Srai, S.K., Unwin, R.J., Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 553 (2003), 137–145.
-
(2003)
J Physiol
, vol.553
, pp. 137-145
-
-
Marks, J.1
Carvou, N.J.C.2
Debnam, E.S.3
Srai, S.K.4
Unwin, R.J.5
-
131
-
-
0033996983
-
+-glucose cotransporter gene, SGLT1, by HNF-1 and Sp1
-
+-glucose cotransporter gene, SGLT1, by HNF-1 and Sp1. Am J Physiol Gastrointest Liver Physiol 278 (2000), G591–G603.
-
(2000)
Am J Physiol Gastrointest Liver Physiol
, vol.278
, pp. G591-G603
-
-
Martin, M.G.1
Wang, J.2
Solorzano-Vargas, R.S.3
Lam, J.T.4
Turk, E.5
Wright, E.M.6
-
132
-
-
0031887925
-
+-dependent and phlorizin-inhibitable transport of glucose and cycasin in brain endothelial cells
-
+-dependent and phlorizin-inhibitable transport of glucose and cycasin in brain endothelial cells. J Neurochem 70 (1998), 772–777.
-
(1998)
J Neurochem
, vol.70
, pp. 772-777
-
-
Matsuoka, T.1
Nishizaki, T.2
Kisby, G.E.3
-
133
-
-
37849031379
-
Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments
-
McConnell, E.L., Basit, A.W., Murdan, S., Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 60 (2008), 63–70.
-
(2008)
J Pharm Pharmacol
, vol.60
, pp. 63-70
-
-
McConnell, E.L.1
Basit, A.W.2
Murdan, S.3
-
134
-
-
1842410679
-
Epidermal growth factor up-regulates sodium-glucose cotransport in enterocyte models in the presence of cholera toxin
-
Mehta, D.I., Horvath, K., Chanasongcram, S., Hill, I.D., Panigrahi, P., Epidermal growth factor up-regulates sodium-glucose cotransport in enterocyte models in the presence of cholera toxin. Parenter Enteral Nutr 21 (1997), 185–191.
-
(1997)
Parenter Enteral Nutr
, vol.21
, pp. 185-191
-
-
Mehta, D.I.1
Horvath, K.2
Chanasongcram, S.3
Hill, I.D.4
Panigrahi, P.5
-
135
-
-
41649087328
-
Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
-
Meng, W., Ellsworth, B.A., Nirschl, A.A., McCann, P.J., Patel, M., Girotra, R.N., et al. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51 (2008), 1145–1149.
-
(2008)
J Med Chem
, vol.51
, pp. 1145-1149
-
-
Meng, W.1
Ellsworth, B.A.2
Nirschl, A.A.3
McCann, P.J.4
Patel, M.5
Girotra, R.N.6
-
136
-
-
84941702063
-
Prevalence of and trends in diabetes among adults in the United States, 1988–2012
-
Menke, A., Casagrande, S., Geiss, L., Cowie, C.C., Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314 (2015), 1021–1029.
-
(2015)
JAMA
, vol.314
, pp. 1021-1029
-
-
Menke, A.1
Casagrande, S.2
Geiss, L.3
Cowie, C.C.4
-
137
-
-
84893827104
-
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
-
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T.V., Tripathy, D., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124 (2014), 509–514.
-
(2014)
J Clin Invest
, vol.124
, pp. 509-514
-
-
Merovci, A.1
Solis-Herrera, C.2
Daniele, G.3
Eldor, R.4
Fiorentino, T.V.5
Tripathy, D.6
-
138
-
-
84937525356
-
A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
-
Michel, M.C., Mayoux, E., Vallon, V., A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn Schmiedeberg's Arch Pharmacol 388 (2015), 801–816.
-
(2015)
Naunyn Schmiedeberg's Arch Pharmacol
, vol.388
, pp. 801-816
-
-
Michel, M.C.1
Mayoux, E.2
Vallon, V.3
-
139
-
-
84973562609
-
Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: A systematic review with indirect comparison meta-analysis
-
Min, S.H., Yoon, J.H., Hahn, S., Cho, Y.M., Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: A systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev, 2016, 10.1002/dmrr.2818.
-
(2016)
Diabetes Metab Res Rev
-
-
Min, S.H.1
Yoon, J.H.2
Hahn, S.3
Cho, Y.M.4
-
140
-
-
7244239341
-
A novel role for glucose 6-phosphatase in the small intestine in the control of glucose homeostasis
-
Mithieux, G., Rajas, F., Gautier-Stein, A., A novel role for glucose 6-phosphatase in the small intestine in the control of glucose homeostasis. J Biol Chem 279 (2004), 44231–44234.
-
(2004)
J Biol Chem
, vol.279
, pp. 44231-44234
-
-
Mithieux, G.1
Rajas, F.2
Gautier-Stein, A.3
-
141
-
-
0026320762
-
Diabetes and glucose transporter gene expression in rat small intestine
-
Miyamoto, K.-I., Hase, K., Taketani, Y., Minami, H., Oka, T., Nakabou, Y., Hagihira, H., Diabetes and glucose transporter gene expression in rat small intestine. Biochem Biophys Res Commun 181 (1991), 1110–1117.
-
(1991)
Biochem Biophys Res Commun
, vol.181
, pp. 1110-1117
-
-
Miyamoto, K.-I.1
Hase, K.2
Taketani, Y.3
Minami, H.4
Oka, T.5
Nakabou, Y.6
Hagihira, H.7
-
142
-
-
84957709696
-
Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport: From bench to bedside
-
Mudaliar, S., Polidori, D., Zambrowicz, B., Henry, R.R., Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport: From bench to bedside. Diabetes Care 38 (2015), 2344–2353.
-
(2015)
Diabetes Care
, vol.38
, pp. 2344-2353
-
-
Mudaliar, S.1
Polidori, D.2
Zambrowicz, B.3
Henry, R.R.4
-
143
-
-
84875135352
-
The SLC2 (GLUT) family of membrane transporters
-
Mueckler, M., Thorens, B., The SLC2 (GLUT) family of membrane transporters. Mol Asp Med 34 (2013), 121–138.
-
(2013)
Mol Asp Med
, vol.34
, pp. 121-138
-
-
Mueckler, M.1
Thorens, B.2
-
144
-
-
84860183617
-
A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors: Systematic review and meta-analysis of randomized trials
-
Musso, G., Gambino, R., Cassader, M., Pagano, G., A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors: Systematic review and meta-analysis of randomized trials. Ann Med 44 (2012), 375–393.
-
(2012)
Ann Med
, vol.44
, pp. 375-393
-
-
Musso, G.1
Gambino, R.2
Cassader, M.3
Pagano, G.4
-
145
-
-
84884554260
-
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice
-
Nagata, T., Fukuzawa, T., Takeda, M., Fukazawa, M., Mori, T., Nihei, T., et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170 (2013), 519–531.
-
(2013)
Br J Pharmacol
, vol.170
, pp. 519-531
-
-
Nagata, T.1
Fukuzawa, T.2
Takeda, M.3
Fukazawa, M.4
Mori, T.5
Nihei, T.6
-
146
-
-
84908066747
-
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
-
Nauck, M.A., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 8 (2014), 1335–1380.
-
(2014)
Drug Des Devel Ther
, vol.8
, pp. 1335-1380
-
-
Nauck, M.A.1
-
147
-
-
80155124676
-
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
-
Nauck, M.A., Del, P.S., Meier, J.J., Duran-Garcia, S., Rohwedder, K., Elze, M., Parikh, S.J., Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34 (2011), 2015–2022.
-
(2011)
Diabetes Care
, vol.34
, pp. 2015-2022
-
-
Nauck, M.A.1
Del, P.S.2
Meier, J.J.3
Duran-Garcia, S.4
Rohwedder, K.5
Elze, M.6
Parikh, S.J.7
-
148
-
-
79952310049
-
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down?
-
Nauck, M.A., Vardarli, I., Deacon, C.F., Holst, J.J., Meier, J.J., Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down?. Diabetologica 54 (2011), 10–18.
-
(2011)
Diabetologica
, vol.54
, pp. 10-18
-
-
Nauck, M.A.1
Vardarli, I.2
Deacon, C.F.3
Holst, J.J.4
Meier, J.J.5
-
149
-
-
84914144323
-
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
-
Nauck, M.A., Del, P.S., Duran-Garcia, S., Rohwedder, K., Langkilde, A.M., Sugg, J., Parikh, S.J., Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 16 (2014), 1111–1120.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 1111-1120
-
-
Nauck, M.A.1
Del, P.S.2
Duran-Garcia, S.3
Rohwedder, K.4
Langkilde, A.M.5
Sugg, J.6
Parikh, S.J.7
-
150
-
-
84882290089
-
Genital mycotic infections in patients with diabetes
-
Nyirjesy, P., Sobel, J.D., Genital mycotic infections in patients with diabetes. Postgrad Med 125 (2013), 33–46.
-
(2013)
Postgrad Med
, vol.125
, pp. 33-46
-
-
Nyirjesy, P.1
Sobel, J.D.2
-
151
-
-
84900823374
-
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
-
Nyirjesy, P., Sobel, J.D., Fung, A., Mayer, C., Capuano, G., Ways, K., Usiskin, K., Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 30 (2014), 1109–1119.
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 1109-1119
-
-
Nyirjesy, P.1
Sobel, J.D.2
Fung, A.3
Mayer, C.4
Capuano, G.5
Ways, K.6
Usiskin, K.7
-
152
-
-
84959366596
-
Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors
-
Ogawa, W., Sakaguchi, K., Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors. J Diabetes Investig 7 (2016), 135–138.
-
(2016)
J Diabetes Investig
, vol.7
, pp. 135-138
-
-
Ogawa, W.1
Sakaguchi, K.2
-
153
-
-
84976371974
-
Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2
-
Ohgaki, R., Wei, L., Yamada, K., Hara, T., Kuriyama, C., Okuda, S., Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther 358 (2016), 94–102.
-
(2016)
J Pharmacol Exp Ther
, vol.358
, pp. 94-102
-
-
Ohgaki, R.1
Wei, L.2
Yamada, K.3
Hara, T.4
Kuriyama, C.5
Okuda, S.6
-
154
-
-
80052572117
-
5a-Carba-b-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
-
Ohtake, Y., Sato, T., Matsuoka, H., Nishimoto, M., Taka, N., Takano, K., et al. 5a-Carba-b-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Bioorg Med Chem 19 (2011), 5334–5341.
-
(2011)
Bioorg Med Chem
, vol.19
, pp. 5334-5341
-
-
Ohtake, Y.1
Sato, T.2
Matsuoka, H.3
Nishimoto, M.4
Taka, N.5
Takano, K.6
-
155
-
-
34547957993
-
Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor
-
O'Keefe, J.H., Bell, D.S., Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 100 (2007), 899–904.
-
(2007)
Am J Cardiol
, vol.100
, pp. 899-904
-
-
O'Keefe, J.H.1
Bell, D.S.2
-
156
-
-
0032850016
-
+-glucose cotransporters, may provide a novel approach to treating diabetes
-
+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48 (1999), 1794–1800.
-
(1999)
Diabetes
, vol.48
, pp. 1794-1800
-
-
Oku, A.1
Ueta, K.2
Arakawa, K.3
Ishihara, T.4
Nawano, M.5
Kuronuma, Y.6
-
157
-
-
84901198078
-
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors
-
Oliva, R.V., Bakris, G.L., Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 8 (2014), 330–339.
-
(2014)
J Am Soc Hypertens
, vol.8
, pp. 330-339
-
-
Oliva, R.V.1
Bakris, G.L.2
-
158
-
-
33845516690
-
Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing
-
O'Malley, D., Reimann, F., Simpson, A.K., Gribble, F.M., Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing. Diabetes 55 (2006), 3381–3386.
-
(2006)
Diabetes
, vol.55
, pp. 3381-3386
-
-
O'Malley, D.1
Reimann, F.2
Simpson, A.K.3
Gribble, F.M.4
-
160
-
-
51549090437
-
Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa
-
Palazzo, M., Gariboldi, S., Zanobbio, L., Selleri, S., Dusio, G.F., Mauro, V., et al. Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa. J Immunol 181 (2008), 3126–3136.
-
(2008)
J Immunol
, vol.181
, pp. 3126-3136
-
-
Palazzo, M.1
Gariboldi, S.2
Zanobbio, L.3
Selleri, S.4
Dusio, G.F.5
Mauro, V.6
-
161
-
-
84866065884
-
Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion
-
Parker, H.E., Adriaenssens, A., Rogers, G., Richards, P., Koepsell, H., Reimann, F., Gribble, F.M., Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia 55 (2012), 2445–2455.
-
(2012)
Diabetologia
, vol.55
, pp. 2445-2455
-
-
Parker, H.E.1
Adriaenssens, A.2
Rogers, G.3
Richards, P.4
Koepsell, H.5
Reimann, F.6
Gribble, F.M.7
-
162
-
-
58149464981
-
Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells
-
Parker, H.E., Habib, A.M., Rogers, G.J., Gribble, F.M., Reimann, F., Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52 (2009), 289–298.
-
(2009)
Diabetologia
, vol.52
, pp. 289-298
-
-
Parker, H.E.1
Habib, A.M.2
Rogers, G.J.3
Gribble, F.M.4
Reimann, F.5
-
163
-
-
84899105421
-
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial
-
Perkins, B.A., Cherney, D.Z., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial. Diabetes Care 37 (2014), 1480–1483.
-
(2014)
Diabetes Care
, vol.37
, pp. 1480-1483
-
-
Perkins, B.A.1
Cherney, D.Z.2
Partridge, H.3
Soleymanlou, N.4
Tschirhart, H.5
Zinman, B.6
-
164
-
-
84962339296
-
Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition
-
Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
-
(2015)
Diabetes Care
, vol.38
, pp. 1687-1693
-
-
Peters, A.L.1
Buschur, E.O.2
Buse, J.B.3
Cohan, P.4
Diner, J.C.5
Hirsch, I.B.6
-
165
-
-
0029839897
-
The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract
-
Playford, R.J., Hanby, A.M., Gschmeissner, S., Peiffer, L.P., Wright, N.A., McGarrity, T., The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract. Gut 39 (1996), 262–266.
-
(1996)
Gut
, vol.39
, pp. 262-266
-
-
Playford, R.J.1
Hanby, A.M.2
Gschmeissner, S.3
Peiffer, L.P.4
Wright, N.A.5
McGarrity, T.6
-
166
-
-
84877865378
-
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized, placebo-controlled study
-
Polidori, D., Sha, S., Mudaliar, S., Ciaraldi, T.P., Ghosh, A., Vaccaro, N., et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized, placebo-controlled study. Diabetes Care 36 (2013), 2154–2161.
-
(2013)
Diabetes Care
, vol.36
, pp. 2154-2161
-
-
Polidori, D.1
Sha, S.2
Mudaliar, S.3
Ciaraldi, T.P.4
Ghosh, A.5
Vaccaro, N.6
-
167
-
-
0034304925
-
HNF1alpha controls renal glucose reabsorption in mouse and man
-
Pontoglio, M., Prie, D., Cheret, C., Doyen, A., Leroy, C., Froguel, P., Velho, G., et al. HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep 1 (2000), 359–365.
-
(2000)
EMBO Rep
, vol.1
, pp. 359-365
-
-
Pontoglio, M.1
Prie, D.2
Cheret, C.3
Doyen, A.4
Leroy, C.5
Froguel, P.6
Velho, G.7
-
168
-
-
84900458799
-
Ipragliflozin: First global approval
-
Poole, R.M., Dungo, R.T., Ipragliflozin: First global approval. Drugs 74 (2014), 611–617.
-
(2014)
Drugs
, vol.74
, pp. 611-617
-
-
Poole, R.M.1
Dungo, R.T.2
-
170
-
-
84876519168
-
LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose
-
Powell, D.R., Smith, M., Greer, J., Harris, A., Zhao, S., DaCosta, C., et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 345 (2013), 250–259.
-
(2013)
J Pharmacol Exp Ther
, vol.345
, pp. 250-259
-
-
Powell, D.R.1
Smith, M.2
Greer, J.3
Harris, A.4
Zhao, S.5
DaCosta, C.6
-
171
-
-
84947786115
-
Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
-
Qiang, S., Nakatsu, Y., Seno, Y., Fujishiro, M., Sakoda, H., Kushiyama, A., et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr, 7, 2015, 104.
-
(2015)
Diabetol Metab Syndr
, vol.7
, pp. 104
-
-
Qiang, S.1
Nakatsu, Y.2
Seno, Y.3
Fujishiro, M.4
Sakoda, H.5
Kushiyama, A.6
-
172
-
-
0037739964
-
Post-challenge hyperglycaemia is associated with premature death and macrovascular complications
-
Qiao, Q., Tuomilehto, J., Borch-Johnsen, K., Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 46:Suppl 1 (2003), M17–M21.
-
(2003)
Diabetologia
, vol.46
, pp. M17-M21
-
-
Qiao, Q.1
Tuomilehto, J.2
Borch-Johnsen, K.3
-
173
-
-
84946491938
-
Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats
-
Rafiq, K., Fujisawa, Y., Sherajee, S.J., Rahman, A., Sufiun, A., Kobori, H., et al. Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia 58 (2015), 2885–2898.
-
(2015)
Diabetologia
, vol.58
, pp. 2885-2898
-
-
Rafiq, K.1
Fujisawa, Y.2
Sherajee, S.J.3
Rahman, A.4
Sufiun, A.5
Kobori, H.6
-
174
-
-
33644688031
-
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
-
Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54 (2005), 3427–3434.
-
(2005)
Diabetes
, vol.54
, pp. 3427-3434
-
-
Rahmoune, H.1
Thompson, P.W.2
Ward, J.M.3
Smith, C.D.4
Hong, G.5
Brown, J.6
-
175
-
-
33947573919
-
Sensing of glucose in the gastrointestinal tract
-
Raybould, H.E., Sensing of glucose in the gastrointestinal tract. Auton Neurosci 133 (2007), 86–90.
-
(2007)
Auton Neurosci
, vol.133
, pp. 86-90
-
-
Raybould, H.E.1
-
176
-
-
56449093424
-
Glucose sensing in L cells: A primary cell study
-
Reimann, F., Habib, A.M., Tolhurst, G., Parker, H.E., Rogers, G.J., Gribble, F.M., Glucose sensing in L cells: A primary cell study. Cell Metab 8 (2008), 532–539.
-
(2008)
Cell Metab
, vol.8
, pp. 532-539
-
-
Reimann, F.1
Habib, A.M.2
Tolhurst, G.3
Parker, H.E.4
Rogers, G.J.5
Gribble, F.M.6
-
177
-
-
84882247018
-
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors
-
Ren, J., Bollu, L.R., Su, F., Gao, G., Xu, L., Huang, W.C., et al. EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors. Prostate 73 (2013), 1453–1461.
-
(2013)
Prostate
, vol.73
, pp. 1453-1461
-
-
Ren, J.1
Bollu, L.R.2
Su, F.3
Gao, G.4
Xu, L.5
Huang, W.C.6
-
179
-
-
84908332537
-
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial
-
Ridderstrale, M., Andersen, K.R., Zeller, C., Kim, G., Woerle, H.J., Broedl, U.C., Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 691–700.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 691-700
-
-
Ridderstrale, M.1
Andersen, K.R.2
Zeller, C.3
Kim, G.4
Woerle, H.J.5
Broedl, U.C.6
-
180
-
-
84892576563
-
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
-
Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D.R., et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306 (2014), F188–F193.
-
(2014)
Am J Physiol Renal Physiol
, vol.306
, pp. F188-F193
-
-
Rieg, T.1
Masuda, T.2
Gerasimova, M.3
Mayoux, E.4
Platt, K.5
Powell, D.R.6
-
181
-
-
84901491136
-
Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis
-
Rijkers, A.P., Valkema, R., Duivenvoorden, H.J., van Eijck, C.H., Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol 40 (2014), 794–804.
-
(2014)
Eur J Surg Oncol
, vol.40
, pp. 794-804
-
-
Rijkers, A.P.1
Valkema, R.2
Duivenvoorden, H.J.3
van Eijck, C.H.4
-
182
-
-
84962069581
-
Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes
-
Rosenstock, J., Chuck, L., Gonzalez-Ortiz, M., Merton, K., Craig, J., Capuano, G., Qiu, R., Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care 39 (2016), 353–362.
-
(2016)
Diabetes Care
, vol.39
, pp. 353-362
-
-
Rosenstock, J.1
Chuck, L.2
Gonzalez-Ortiz, M.3
Merton, K.4
Craig, J.5
Capuano, G.6
Qiu, R.7
-
183
-
-
84928201032
-
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin
-
Rosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., Iqbal, N., Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38 (2015), 376–383.
-
(2015)
Diabetes Care
, vol.38
, pp. 376-383
-
-
Rosenstock, J.1
Hansen, L.2
Zee, P.3
Li, Y.4
Cook, W.5
Hirshberg, B.6
Iqbal, N.7
-
184
-
-
84903511385
-
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
-
Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H.J., Broedl, U.C., Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37 (2014), 1815–1823.
-
(2014)
Diabetes Care
, vol.37
, pp. 1815-1823
-
-
Rosenstock, J.1
Jelaska, A.2
Frappin, G.3
Salsali, A.4
Kim, G.5
Woerle, H.J.6
Broedl, U.C.7
-
185
-
-
0025280111
-
Glucose toxicity
-
Rossetti, L., Giaccari, A., DeFronzo, R.A., Glucose toxicity. Diabetes Care 13 (1990), 610–630.
-
(1990)
Diabetes Care
, vol.13
, pp. 610-630
-
-
Rossetti, L.1
Giaccari, A.2
DeFronzo, R.A.3
-
186
-
-
0023275573
-
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats
-
Rossetti, L., Smith, D., Shulman, G.I., Papachristou, D., DeFronzo, R.A., Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79 (1987), 1510–1515.
-
(1987)
J Clin Invest
, vol.79
, pp. 1510-1515
-
-
Rossetti, L.1
Smith, D.2
Shulman, G.I.3
Papachristou, D.4
DeFronzo, R.A.5
-
187
-
-
84917741721
-
Hypothalamic glucose sensing: Making ends meet
-
Routh, V.H., Hao, L., Santiago, A.M., Sheng, Z., Zhou, C., Hypothalamic glucose sensing: Making ends meet. Front Syst Neurosci, 8, 2014, 236.
-
(2014)
Front Syst Neurosci
, vol.8
, pp. 236
-
-
Routh, V.H.1
Hao, L.2
Santiago, A.M.3
Sheng, Z.4
Zhou, C.5
-
188
-
-
84866656037
-
Glomerular hyperfiltration and renal disease progression in type 2 diabetes
-
Ruggenenti, P., Porrini, E.L., Gaspari, F., Motterlini, N., Cannata, A., Carrara, F., et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 35 (2012), 2061–2068.
-
(2012)
Diabetes Care
, vol.35
, pp. 2061-2068
-
-
Ruggenenti, P.1
Porrini, E.L.2
Gaspari, F.3
Motterlini, N.4
Cannata, A.5
Carrara, F.6
-
189
-
-
84963966467
-
Clinical implications of cardiovascular outcome trials in type 2 diabetes: From DCCT to EMPA-REG
-
Ryden, L., Shahim, B., Mellbin, L., Clinical implications of cardiovascular outcome trials in type 2 diabetes: From DCCT to EMPA-REG. Clin Ther 38 (2016), 1279–1287, 10.1016/j.clinthera.2016.03.035.
-
(2016)
Clin Ther
, vol.38
, pp. 1279-1287
-
-
Ryden, L.1
Shahim, B.2
Mellbin, L.3
-
190
-
-
32644481587
-
High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule
-
Saad, S., Stevens, V.A., Wassef, L., Poronnik, P., Kelly, D.J., Gilbert, R.E., Pollock, C.A., High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney Int 68 (2005), 985–997.
-
(2005)
Kidney Int
, vol.68
, pp. 985-997
-
-
Saad, S.1
Stevens, V.A.2
Wassef, L.3
Poronnik, P.4
Kelly, D.J.5
Gilbert, R.E.6
Pollock, C.A.7
-
191
-
-
48449097409
-
The locus for hypoglycemic detection shifts with the rate of fall in glycemia: The role of portal-superior mesenteric vein glucose sensing
-
Saberi, M., Bohland, M., Donovan, C.M., The locus for hypoglycemic detection shifts with the rate of fall in glycemia: The role of portal-superior mesenteric vein glucose sensing. Diabetes 57 (2008), 1380–1386.
-
(2008)
Diabetes
, vol.57
, pp. 1380-1386
-
-
Saberi, M.1
Bohland, M.2
Donovan, C.M.3
-
193
-
-
0025268248
-
Ventromedial hypothalamic lesions attenuate responses of sympathetic nerves to carotid arterial infusions of glucose and insulin
-
Sakaguchi, T., Bray, G.A., Ventromedial hypothalamic lesions attenuate responses of sympathetic nerves to carotid arterial infusions of glucose and insulin. Int J Obes 14 (1990), 127–133.
-
(1990)
Int J Obes
, vol.14
, pp. 127-133
-
-
Sakaguchi, T.1
Bray, G.A.2
-
194
-
-
84961801299
-
Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials
-
Sakai, S., Kaku, K., Seino, Y., Inagaki, N., Haneda, M., Sasaki, T., et al. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials. Clin Ther 38 (2016), 843–862.
-
(2016)
Clin Ther
, vol.38
, pp. 843-862
-
-
Sakai, S.1
Kaku, K.2
Seino, Y.3
Inagaki, N.4
Haneda, M.5
Sasaki, T.6
-
195
-
-
75749094398
-
Familial renal glucosuria and SGLT2: From a mendelian trait to a therapeutic target
-
Santer, R., Calado, J., Familial renal glucosuria and SGLT2: From a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5 (2010), 133–141.
-
(2010)
Clin J Am Soc Nephrol
, vol.5
, pp. 133-141
-
-
Santer, R.1
Calado, J.2
-
196
-
-
10744229025
-
Molecular analysis of the SGLT2 gene in patients with renal glucosuria
-
Santer, R., Kinner, M., Lassen, C.L., Schneppenheim, R., Eggert, P., Bald, M., et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14 (2003), 2873–2882.
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 2873-2882
-
-
Santer, R.1
Kinner, M.2
Lassen, C.L.3
Schneppenheim, R.4
Eggert, P.5
Bald, M.6
-
197
-
-
84964507777
-
SGLT2 inhibition and cardiovascular events: Why did EMPA-REG outcomes surprise and what were the likely mechanisms?
-
Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 inhibition and cardiovascular events: Why did EMPA-REG outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339.
-
(2016)
Diabetologia
, vol.59
, pp. 1333-1339
-
-
Sattar, N.1
McLaren, J.2
Kristensen, S.L.3
Preiss, D.4
McMurray, J.J.5
-
198
-
-
84938152222
-
Functional expression of sodium-glucose transporters in cancer
-
Scafoglio, C., Hirayama, B.A., Kepe, V., Liu, J., Ghezzi, C., Satyamurthy, N., et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A 112 (2015), E4111–E4119.
-
(2015)
Proc Natl Acad Sci U S A
, vol.112
, pp. E4111-E4119
-
-
Scafoglio, C.1
Hirayama, B.A.2
Kepe, V.3
Liu, J.4
Ghezzi, C.5
Satyamurthy, N.6
-
199
-
-
84923791994
-
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
-
Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
-
(2015)
Drugs
, vol.75
, pp. 33-59
-
-
Scheen, A.J.1
-
200
-
-
84933676007
-
Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
-
Scheen, A.J., Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet 54 (2015), 691–708.
-
(2015)
Clin Pharmacokinet
, vol.54
, pp. 691-708
-
-
Scheen, A.J.1
-
201
-
-
84891784200
-
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
-
Schernthaner, G., Gross, J.L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36 (2013), 2508–2515.
-
(2013)
Diabetes Care
, vol.36
, pp. 2508-2515
-
-
Schernthaner, G.1
Gross, J.L.2
Rosenstock, J.3
Guarisco, M.4
Fu, M.5
Yee, J.6
-
202
-
-
0032948191
-
2, in glucose absorption via the sodium dependent glucose transporter-1 in rat intestine
-
2, in glucose absorption via the sodium dependent glucose transporter-1 in rat intestine. Gut 44 (1999), 490–496.
-
(1999)
Gut
, vol.44
, pp. 490-496
-
-
Scholtka, B.1
Stümpel, F.2
Jungermann, K.3
-
203
-
-
84861127361
-
Role of gut nutrient sensing in stimulating appetite and conditioning food preferences
-
Sclafani, A., Ackroff, K., Role of gut nutrient sensing in stimulating appetite and conditioning food preferences. Am J Physiol Regul Integr Comp Physiol 302 (2012), R1119–R1133.
-
(2012)
Am J Physiol Regul Integr Comp Physiol
, vol.302
, pp. R1119-R1133
-
-
Sclafani, A.1
Ackroff, K.2
-
204
-
-
84984607321
-
SGLT1 sugar transporter/sensor is required for post-oral glucose appetition
-
Sclafani, A., Koepsell, H., Ackroff, K., SGLT1 sugar transporter/sensor is required for post-oral glucose appetition. Am J Physiol Regul Integr Comp Physiol 310 (2016), R631–R639.
-
(2016)
Am J Physiol Regul Integr Comp Physiol
, vol.310
, pp. R631-R639
-
-
Sclafani, A.1
Koepsell, H.2
Ackroff, K.3
-
205
-
-
79956331954
-
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
-
Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13 (2011), 669–672.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 669-672
-
-
Sha, S.1
Devineni, D.2
Ghosh, A.3
Polidori, D.4
Chien, S.5
Wexler, D.6
-
206
-
-
84991698539
-
A Renal Olfactory Receptor Aids in Kidney Glucose Handling
-
Shepard, B.D., Cheval, L., Peterlin, Z., Firestein, S., Koepsell, H., Doucet, A., et al. A renal olfactory receptor aids in kidney glucose handling. Sci Rep, 2016 6, 35215.
-
(2016)
Scientific Reports
, vol.6
, Issue.14
-
-
Shepard, B.D.1
Cheval, L.2
Peterlin,, Z.3
Firestein, S.4
Koepsell, H.5
Doucet, A.6
Pluznick, J.L.7
-
207
-
-
84864118760
-
KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models
-
Shibazaki, T., Tomae, M., Ishikawa-Takemura, Y., Fushimi, N., Itoh, F., Yamada, M., Isaji, M., KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 342 (2012), 288–296.
-
(2012)
J Pharmacol Exp Ther
, vol.342
, pp. 288-296
-
-
Shibazaki, T.1
Tomae, M.2
Ishikawa-Takemura, Y.3
Fushimi, N.4
Itoh, F.5
Yamada, M.6
Isaji, M.7
-
208
-
-
24344503323
-
Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients
-
Shiraiwa, T., Kaneto, H., Miyatsuka, T., Kato, K., Yamamoto, K., Kawashima, A., et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 336 (2005), 339–345.
-
(2005)
Biochem Biophys Res Commun
, vol.336
, pp. 339-345
-
-
Shiraiwa, T.1
Kaneto, H.2
Miyatsuka, T.3
Kato, K.4
Yamamoto, K.5
Kawashima, A.6
-
209
-
-
84960433486
-
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
-
Shyangdan, D.S., Uthman, O.A., Waugh, N., SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open, 6, 2016, e009417.
-
(2016)
BMJ Open
, vol.6
-
-
Shyangdan, D.S.1
Uthman, O.A.2
Waugh, N.3
-
210
-
-
84971635917
-
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
-
Song, P., Onishi, A., Koepsell, H., Vallon, V., Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets, 2016, 10.1517/14728222.2016.1168808.
-
(2016)
Expert Opin Ther Targets
-
-
Song, P.1
Onishi, A.2
Koepsell, H.3
Vallon, V.4
-
211
-
-
0031791027
-
Enteric glucagon 37 rather than pancreatic glucagon 29 stimulates glucose absorption in rat intestine
-
Stümpel, F., Scholtka, B., Hunger, A., Jungermann, K., Enteric glucagon 37 rather than pancreatic glucagon 29 stimulates glucose absorption in rat intestine. Gastroenterology 115 (1998), 1163–1171.
-
(1998)
Gastroenterology
, vol.115
, pp. 1163-1171
-
-
Stümpel, F.1
Scholtka, B.2
Hunger, A.3
Jungermann, K.4
-
212
-
-
0034519317
-
Stimulation by portal insulin of intestinal glucose absorption via hepatoenteral nerves and prostaglandin E2 in the isolated, jointly perfused small intestine and liver of the rat
-
Stümpel, F., Scholtka, B., Jungermann, K., Stimulation by portal insulin of intestinal glucose absorption via hepatoenteral nerves and prostaglandin E2 in the isolated, jointly perfused small intestine and liver of the rat. Ann N Y Acad Sci 915 (2000), 111–116.
-
(2000)
Ann N Y Acad Sci
, vol.915
, pp. 111-116
-
-
Stümpel, F.1
Scholtka, B.2
Jungermann, K.3
-
213
-
-
84861536065
-
Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice
-
Suzuki, M., Honda, K., Fukazawa, M., Ozawa, K., Hagita, H., Kawai, T., et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341 (2012), 692–701.
-
(2012)
J Pharmacol Exp Ther
, vol.341
, pp. 692-701
-
-
Suzuki, M.1
Honda, K.2
Fukazawa, M.3
Ozawa, K.4
Hagita, H.5
Kawai, T.6
-
214
-
-
57949111356
-
Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats
-
Tabatabai, N.M., Sharma, M., Blumenthal, S.S., Petering, D.H., Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract 83 (2009), e27–e30.
-
(2009)
Diabetes Res Clin Pract
, vol.83
, pp. e27-e30
-
-
Tabatabai, N.M.1
Sharma, M.2
Blumenthal, S.S.3
Petering, D.H.4
-
215
-
-
84866541730
-
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice
-
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci 120 (2012), 36–44.
-
(2012)
J Pharmacol Sci
, vol.120
, pp. 36-44
-
-
Tahara, A.1
Kurosaki, E.2
Yokono, M.3
Yamajuku, D.4
Kihara, R.5
Hayashizaki, Y.6
-
216
-
-
84885476895
-
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
-
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715 (2013), 246–255.
-
(2013)
Eur J Pharmacol
, vol.715
, pp. 246-255
-
-
Tahara, A.1
Kurosaki, E.2
Yokono, M.3
Yamajuku, D.4
Kihara, R.5
Hayashizaki, Y.6
-
217
-
-
84959890006
-
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
-
Tahara, A., Takasu, T., Yokono, M., Imamura, M., Kurosaki, E., Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci 130 (2016), 159–169.
-
(2016)
J Pharmacol Sci
, vol.130
, pp. 159-169
-
-
Tahara, A.1
Takasu, T.2
Yokono, M.3
Imamura, M.4
Kurosaki, E.5
-
218
-
-
84957586606
-
Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats
-
Takakura, S., Toyoshi, T., Hayashizaki, Y., Takasu, T., Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Life Sci 147 (2016), 125–131.
-
(2016)
Life Sci
, vol.147
, pp. 125-131
-
-
Takakura, S.1
Toyoshi, T.2
Hayashizaki, Y.3
Takasu, T.4
-
219
-
-
0035019788
-
Diurnal rhythmicity in intestinal SGLT-1 function, Vmax, and mRNA expression topography
-
Tavakkolizadeh, A., Berger, U.V., Shen, K.R., Levitsky, L.L., Zinner, M.J., et al. Diurnal rhythmicity in intestinal SGLT-1 function, Vmax, and mRNA expression topography. Am J Physiol Gastrointest Liver Physiol 280 (2001), G209–G215.
-
(2001)
Am J Physiol Gastrointest Liver Physiol
, vol.280
, pp. G209-G215
-
-
Tavakkolizadeh, A.1
Berger, U.V.2
Shen, K.R.3
Levitsky, L.L.4
Zinner, M.J.5
-
220
-
-
84939142605
-
SGLT2 inhibitors may predispose to ketoacidosis
-
Taylor, S.I., Blau, J.E., Rother, K.I., SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100 (2015), 2849–2852.
-
(2015)
J Clin Endocrinol Metab
, vol.100
, pp. 2849-2852
-
-
Taylor, S.I.1
Blau, J.E.2
Rother, K.I.3
-
221
-
-
84867518730
-
Targeting cancer metabolism
-
Teicher, B.A., Linehan, W.M., Helman, L.J., Targeting cancer metabolism. Clin Cancer Res 18 (2012), 5537–5545.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 5537-5545
-
-
Teicher, B.A.1
Linehan, W.M.2
Helman, L.J.3
-
222
-
-
84903528312
-
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice
-
Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One, 9, 2014, e100777.
-
(2014)
PLoS One
, vol.9
-
-
Terami, N.1
Ogawa, D.2
Tachibana, H.3
Hatanaka, T.4
Wada, J.5
Nakatsuka, A.6
-
223
-
-
0030018911
-
+-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives based on a new concept
-
+-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull 44 (1996), 1174–1180.
-
(1996)
Chem Pharm Bull
, vol.44
, pp. 1174-1180
-
-
Tsujihara, K.1
Hongu, M.2
Saito, K.3
Inamasu, M.4
Arakawa, K.5
Oku, A.6
Maisumoto, M.7
-
225
-
-
84855459920
-
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
-
Unger, R.H., Cherrington, A.D., Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. J Clin Invest 122 (2012), 4–12.
-
(2012)
J Clin Invest
, vol.122
, pp. 4-12
-
-
Unger, R.H.1
Cherrington, A.D.2
-
226
-
-
84906924894
-
Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results
-
Usiskin, K., Kline, I., Fung, A., Mayer, C., Meininger, G., Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med 126 (2014), 16–34.
-
(2014)
Postgrad Med
, vol.126
, pp. 16-34
-
-
Usiskin, K.1
Kline, I.2
Fung, A.3
Mayer, C.4
Meininger, G.5
-
227
-
-
79955771730
-
The proximal tubule in the pathophysiology of the diabetic kidney
-
Vallon, V., The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300 (2011), R1009–R1022.
-
(2011)
Am J Physiol Regul Integr Comp Physiol
, vol.300
, pp. R1009-R1022
-
-
Vallon, V.1
-
228
-
-
84921374064
-
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
-
Vallon, V., The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66 (2015), 255–270.
-
(2015)
Annu Rev Med
, vol.66
, pp. 255-270
-
-
Vallon, V.1
-
229
-
-
84892588641
-
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
-
Vallon, V., Gerasimova, M., Rose, M.A., Masuda, T., Satriano, J., Mayoux, E., et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306 (2014), F194–F204.
-
(2014)
Am J Physiol Renal Physiol
, vol.306
, pp. F194-F204
-
-
Vallon, V.1
Gerasimova, M.2
Rose, M.A.3
Masuda, T.4
Satriano, J.5
Mayoux, E.6
-
230
-
-
78651406659
-
SGLT2 mediates glucose reabsorption in the early proximal tubule
-
Vallon, V., Platt, K.A., Cunard, R., Schroth, J., Whaley, J., Thomson, S.C.,.. Rieg, T., SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22 (2011), 104–112.
-
(2011)
J Am Soc Nephrol
, vol.22
, pp. 104-112
-
-
Vallon, V.1
Platt, K.A.2
Cunard, R.3
Schroth, J.4
Whaley, J.5
Thomson, S.C.6
Rieg, T.7
-
231
-
-
84872400230
-
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
-
Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K.A., Koepsell, H., et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304 (2012), F156–F167.
-
(2012)
Am J Physiol Renal Physiol
, vol.304
, pp. F156-F167
-
-
Vallon, V.1
Rose, M.2
Gerasimova, M.3
Satriano, J.4
Platt, K.A.5
Koepsell, H.6
-
232
-
-
84882251091
-
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis
-
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
-
(2013)
Ann Intern Med
, vol.159
, pp. 262-274
-
-
Vasilakou, D.1
Karagiannis, T.2
Athanasiadou, E.3
Mainou, M.4
Liakos, A.5
Bekiari, E.6
-
234
-
-
0034786793
-
+/glucose cotransporter SGLT1 gene. Role of HNF-1 in glucose activation of promoter function
-
+/glucose cotransporter SGLT1 gene. Role of HNF-1 in glucose activation of promoter function. Eur J Biochem 268 (2001), 5460–5470.
-
(2001)
Eur J Biochem
, vol.268
, pp. 5460-5470
-
-
Vayro, S.1
Wood, I.S.2
Dyer, J.3
Shirazi-Beechey, S.P.4
-
236
-
-
0035879385
-
Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat
-
Vestri, S., Okamoto, M.M., de Freitas, H.S., Aparecida dos Santos, R., Nunes, M.T., Morimatsu, M., et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 182 (2001), 105–112.
-
(2001)
J Membr Biol
, vol.182
, pp. 105-112
-
-
Vestri, S.1
Okamoto, M.M.2
de Freitas, H.S.3
Aparecida dos Santos, R.4
Nunes, M.T.5
Morimatsu, M.6
-
239
-
-
84958158188
-
Phosphorylation of RS1 (RSC1A1) steers inhibition of different exocytotic pathways for glucose transporter SGLT1 and nucleoside transporter CNT1 and a RS1 derived peptide inhibits glucose absorption
-
Veyhl-Wichmann, M., Friedrich, A., Vernaleken, A., Singh, S., Kipp, H., Gorboulev, V., et al. Phosphorylation of RS1 (RSC1A1) steers inhibition of different exocytotic pathways for glucose transporter SGLT1 and nucleoside transporter CNT1 and a RS1 derived peptide inhibits glucose absorption. Mol Pharmacol 89 (2016), 118–132.
-
(2016)
Mol Pharmacol
, vol.89
, pp. 118-132
-
-
Veyhl-Wichmann, M.1
Friedrich, A.2
Vernaleken, A.3
Singh, S.4
Kipp, H.5
Gorboulev, V.6
-
240
-
-
0001095690
-
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
-
Vilsboll, T., Krarup, T., Deacon, C.F., Madsbad, S., Holst, J.J., Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001), 609–613.
-
(2001)
Diabetes
, vol.50
, pp. 609-613
-
-
Vilsboll, T.1
Krarup, T.2
Deacon, C.F.3
Madsbad, S.4
Holst, J.J.5
-
241
-
-
79959320677
-
Intestinal glucose-induced calcium-calmodulin kinase signaling in the gut-brain axis in awake rats
-
Vincent, K.M., Sharp, J.W., Raybould, H.E., Intestinal glucose-induced calcium-calmodulin kinase signaling in the gut-brain axis in awake rats. Neurogastroenterol Motil 23 (2011), e282–e293.
-
(2011)
Neurogastroenterol Motil
, vol.23
, pp. e282-e293
-
-
Vincent, K.M.1
Sharp, J.W.2
Raybould, H.E.3
-
242
-
-
77952803960
-
Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients
-
von Lewinski, D., Rainer, P.P., Gasser, R., Huber, M.S., Khafaga, M., Wilhelm, B., et al. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism 59 (2010), 1020–1028.
-
(2010)
Metabolism
, vol.59
, pp. 1020-1028
-
-
von Lewinski, D.1
Rainer, P.P.2
Gasser, R.3
Huber, M.S.4
Khafaga, M.5
Wilhelm, B.6
-
243
-
-
33846406395
-
Imino sugars are potent agonists of the human glucose sensor SGLT3
-
Voss, A.A., Dίez-Sampedro, A., Hirayama, B.A., Loo, D.D.F., Wright, E.M., Imino sugars are potent agonists of the human glucose sensor SGLT3. Mol Pharmacol 71 (2007), 628–634.
-
(2007)
Mol Pharmacol
, vol.71
, pp. 628-634
-
-
Voss, A.A.1
Dίez-Sampedro, A.2
Hirayama, B.A.3
Loo, D.D.F.4
Wright, E.M.5
-
244
-
-
84943234625
-
+-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
-
+-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467 (2015), 1881–1898.
-
(2015)
Pflugers Arch
, vol.467
, pp. 1881-1898
-
-
Vrhovac, I.1
Balen, E.D.2
Klessen, D.3
Burger, C.4
Breljak, D.5
Kraus, O.6
-
246
-
-
84979895487
-
Empagliflozin and progression of kidney disease in type 2 diabetes
-
Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
-
(2016)
N Engl J Med
, vol.375
, pp. 323-334
-
-
Wanner, C.1
Inzucchi, S.E.2
Lachin, J.M.3
Fitchett, D.4
von Eynatten, M.5
Mattheus, M.6
-
247
-
-
84875150979
-
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
-
Washburn, W.N., Poucher, S.M., Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 22 (2013), 463–486.
-
(2013)
Expert Opin Investig Drugs
, vol.22
, pp. 463-486
-
-
Washburn, W.N.1
Poucher, S.M.2
-
248
-
-
42949176742
-
Survival of cancer cells is maintained by EGFR independent of its kinase activity
-
Weihua, Z., Tsan, R., Huang, W.-C., Wu, Q., Chiu, C.-H., Fidler, I.J., Hung, M.-C., Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13 (2008), 385–393.
-
(2008)
Cancer Cell
, vol.13
, pp. 385-393
-
-
Weihua, Z.1
Tsan, R.2
Huang, W.-C.3
Wu, Q.4
Chiu, C.-H.5
Fidler, I.J.6
Hung, M.-C.7
-
249
-
-
84964010047
-
The kidney and type 2 diabetes mellitus: Therapeutic implications of SGLT2 inhibitors
-
Weir, M.R., The kidney and type 2 diabetes mellitus: Therapeutic implications of SGLT2 inhibitors. Postgrad Med 128 (2016), 290–298.
-
(2016)
Postgrad Med
, vol.128
, pp. 290-298
-
-
Weir, M.R.1
-
250
-
-
84858323889
-
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial
-
Wilding, J.P., Woo, V., Soler, N.G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med 156 (2012), 405–415.
-
(2012)
Ann Intern Med
, vol.156
, pp. 405-415
-
-
Wilding, J.P.1
Woo, V.2
Soler, N.G.3
Pahor, A.4
Sugg, J.5
Rohwedder, K.6
Parikh, S.7
-
251
-
-
0032485927
-
Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo
-
Williams, S.B., Goldfine, A.B., Timimi, F.K., Ting, H.H., Roddy, M.A., Simonson, D.C., Creager, M.A., Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97 (1998), 1695–1701.
-
(1998)
Circulation
, vol.97
, pp. 1695-1701
-
-
Williams, S.B.1
Goldfine, A.B.2
Timimi, F.K.3
Ting, H.H.4
Roddy, M.A.5
Simonson, D.C.6
Creager, M.A.7
-
252
-
-
84920263464
-
The impact of high-fat diet on metabolism and immune defense in small intestine mucosa
-
Wisniewski, J.R., Friedrich, A., Keller, T., Mann, M., Koepsell, H., The impact of high-fat diet on metabolism and immune defense in small intestine mucosa. J Proteome Res 14 (2015), 353–365.
-
(2015)
J Proteome Res
, vol.14
, pp. 353-365
-
-
Wisniewski, J.R.1
Friedrich, A.2
Keller, T.3
Mann, M.4
Koepsell, H.5
-
253
-
-
84875153197
-
Glucose transport families SLC5 and SLC 50
-
Wright, E.M., Glucose transport families SLC5 and SLC 50. Mol Asp Med 34 (2013), 183–196.
-
(2013)
Mol Asp Med
, vol.34
, pp. 183-196
-
-
Wright, E.M.1
-
255
-
-
78651349221
-
Biology of human sodium glucose transporters
-
Wright, E.M., Loo, D.D.F., Hirayama, B.A., Biology of human sodium glucose transporters. Physiol Rev 91 (2011), 733–794.
-
(2011)
Physiol Rev
, vol.91
, pp. 733-794
-
-
Wright, E.M.1
Loo, D.D.F.2
Hirayama, B.A.3
-
256
-
-
84869487801
-
Post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage through the cerebral sodium-glucose transporter
-
Yamazaki, Y., Harada, S., Tokuyama, S., Post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage through the cerebral sodium-glucose transporter. Brain Res 1489 (2012), 113–120.
-
(2012)
Brain Res
, vol.1489
, pp. 113-120
-
-
Yamazaki, Y.1
Harada, S.2
Tokuyama, S.3
-
257
-
-
84975229499
-
Sodium transport through the cerebral sodium-glucose transporter exacerbates neuron damage during cerebral ischaemia
-
Yamazaki, Y., Harada, S., Wada, T., Yoshida, S., Tokuyama, S., Sodium transport through the cerebral sodium-glucose transporter exacerbates neuron damage during cerebral ischaemia. J Pharm Pharmacol 68 (2016), 922–931, 10.1111/jphp.12571.
-
(2016)
J Pharm Pharmacol
, vol.68
, pp. 922-931
-
-
Yamazaki, Y.1
Harada, S.2
Wada, T.3
Yoshida, S.4
Tokuyama, S.5
-
258
-
-
84944718007
-
Activation of cerebral sodium-glucose transporter type 1 function mediated by post-ischemic hyperglycemia exacerbates the development of cerebral ischemia
-
Yamazaki, Y., Ogihara, S., Harada, S., Tokuyama, S., Activation of cerebral sodium-glucose transporter type 1 function mediated by post-ischemic hyperglycemia exacerbates the development of cerebral ischemia. Neuroscience 310 (2015), 674–685.
-
(2015)
Neuroscience
, vol.310
, pp. 674-685
-
-
Yamazaki, Y.1
Ogihara, S.2
Harada, S.3
Tokuyama, S.4
-
259
-
-
84904525477
-
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy
-
Yamout, H., Perkovic, V., Davies, M., Woo, V., de Zeeuw, D., Mayer, C., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 40 (2014), 64–74.
-
(2014)
Am J Nephrol
, vol.40
, pp. 64-74
-
-
Yamout, H.1
Perkovic, V.2
Davies, M.3
Woo, V.4
de Zeeuw, D.5
Mayer, C.6
-
260
-
-
0032829063
-
Hypothalamic glucose sensor: Similarities to and differences from pancreatic beta-cell mechanisms
-
Yang, X., Kow, L.-M., Funabashi, T., Mobbs, C.V., Hypothalamic glucose sensor: Similarities to and differences from pancreatic beta-cell mechanisms. Diabetes 48 (1999), 1763–1772.
-
(1999)
Diabetes
, vol.48
, pp. 1763-1772
-
-
Yang, X.1
Kow, L.-M.2
Funabashi, T.3
Mobbs, C.V.4
-
261
-
-
27744547067
-
SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: A novel cellular rescue mechanism?
-
Yu, L.C., Flynn, A.N., Turner, J.R., Buret, A.G., SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: A novel cellular rescue mechanism?. FASEB J 19 (2005), 1822–1835.
-
(2005)
FASEB J
, vol.19
, pp. 1822-1835
-
-
Yu, L.C.1
Flynn, A.N.2
Turner, J.R.3
Buret, A.G.4
-
262
-
-
84873336411
-
Regional distribution of SGLT activity in rat brain in vivo
-
Yu, A.S., Hirayama, B.A., Timbol, G., Liu, J., Dίez-Sampedro, A., Kepe, V., et al. Regional distribution of SGLT activity in rat brain in vivo. Am J Physiol Cell Physiol 304 (2013), C240–C247.
-
(2013)
Am J Physiol Cell Physiol
, vol.304
, pp. C240-C247
-
-
Yu, A.S.1
Hirayama, B.A.2
Timbol, G.3
Liu, J.4
Dίez-Sampedro, A.5
Kepe, V.6
-
263
-
-
33748618171
-
LPS/CD14 activation triggers SGLT-1-mediated glucose uptake and cell rescue in intestinal epithelial cells via early apoptotic signals upstream of caspase-3
-
Yu, L.C., Turner, J.R., Buret, A.G., LPS/CD14 activation triggers SGLT-1-mediated glucose uptake and cell rescue in intestinal epithelial cells via early apoptotic signals upstream of caspase-3. Exp Cell Res 312 (2006), 3276–3286.
-
(2006)
Exp Cell Res
, vol.312
, pp. 3276-3286
-
-
Yu, L.C.1
Turner, J.R.2
Buret, A.G.3
-
264
-
-
84969915634
-
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis
-
Zaccardi, F., Webb, D.R., Htike, Z.Z., Youssef, D., Khunti, K., Davies, M.J., Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab 18 (2016), 783–794, 10.1111/dom.12670.
-
(2016)
Diabetes Obes Metab
, vol.18
, pp. 783-794
-
-
Zaccardi, F.1
Webb, D.R.2
Htike, Z.Z.3
Youssef, D.4
Khunti, K.5
Davies, M.J.6
-
265
-
-
84864146681
-
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial
-
Zambrowicz, B., Freiman, J., Brown, P.M., Frazier, K.S., Turnage, A., Bronner, J., et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 92 (2012), 158–169.
-
(2012)
Clin Pharmacol Ther
, vol.92
, pp. 158-169
-
-
Zambrowicz, B.1
Freiman, J.2
Brown, P.M.3
Frazier, K.S.4
Turnage, A.5
Bronner, J.6
-
266
-
-
84889670998
-
Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes
-
Zhang, Q., Ramracheya, R., Lahmann, C., Tarasov, A., Bengtsson, M., Braha, O., et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab 18 (2013), 871–882.
-
(2013)
Cell Metab
, vol.18
, pp. 871-882
-
-
Zhang, Q.1
Ramracheya, R.2
Lahmann, C.3
Tarasov, A.4
Bengtsson, M.5
Braha, O.6
-
267
-
-
84954104372
-
Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease
-
Zhang, Y., Thai, K., Kepecs, D.M., Gilbert, R.E., Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS One, 11, 2016, e0144640.
-
(2016)
PLoS One
, vol.11
-
-
Zhang, Y.1
Thai, K.2
Kepecs, D.M.3
Gilbert, R.E.4
-
268
-
-
84963706055
-
Sodium intake regulates glucose homeostasis through the PPARdelta/adiponectin-mediated SGLT2 pathway
-
Zhao, Y., Gao, P., Sun, F., Li, Q., Chen, J., Yu, H., et al. Sodium intake regulates glucose homeostasis through the PPARdelta/adiponectin-mediated SGLT2 pathway. Cell Metab 23 (2016), 699–711.
-
(2016)
Cell Metab
, vol.23
, pp. 699-711
-
-
Zhao, Y.1
Gao, P.2
Sun, F.3
Li, Q.4
Chen, J.5
Yu, H.6
-
270
-
-
0032945577
-
Whole body glucose metabolism
-
Zierler, K., Whole body glucose metabolism. Am J Phys 276 (1999), E409–E426.
-
(1999)
Am J Phys
, vol.276
, pp. E409-E426
-
-
Zierler, K.1
-
271
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
Fitchett, D.4
Bluhmki, E.5
Hantel, S.6
|